Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Alzheimer's Disease

  Free Subscription


Articles published in Alzheimers Dement

Retrieve available abstracts of 399 articles:
HTML format



Single Articles


    June 2022
  1. WINGO TS, Gerasimov ES, Canon SM, Lah JJ, et al
    Alzheimer's disease genetic burden is associated with mid-life depression among persons with normal cognition.
    Alzheimers Dement. 2022 Jun 21. doi: 10.1002/alz.12716.
    PubMed     Abstract available


  2. CULLEN NC, Janelidze S, Mattsson-Carlgren N, Palmqvist S, et al
    Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models.
    Alzheimers Dement. 2022 Jun 14. doi: 10.1002/alz.12706.
    PubMed     Abstract available


  3. DELVENNE A, Gobom J, Tijms B, Bos I, et al
    Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology.
    Alzheimers Dement. 2022 Jun 14. doi: 10.1002/alz.12713.
    PubMed     Abstract available


  4. SINGH NA, Tosakulwong N, Graff-Radford J, Machulda MM, et al
    APOE epsilon4 influences medial temporal atrophy and tau deposition in atypical Alzheimer's disease.
    Alzheimers Dement. 2022 Jun 12. doi: 10.1002/alz.12711.
    PubMed     Abstract available


  5. RISCHEL EB, Gejl M, Brock B, Rungby J, et al
    In Alzheimer's disease, amyloid beta accumulation is a protective mechanism that ultimately fails.
    Alzheimers Dement. 2022 Jun 8. doi: 10.1002/alz.12701.
    PubMed     Abstract available


  6. GAO F, Lv X, Dai L, Wang Q, et al
    A combination model of AD biomarkers revealed by machine learning precisely predicts Alzheimer's dementia: China Aging and Neurodegenerative Initiative (CANDI) study.
    Alzheimers Dement. 2022 Jun 6. doi: 10.1002/alz.12700.
    PubMed     Abstract available


  7. GUSTAVSSON A, Norton N, Fast T, Frolich L, et al
    Global estimates on the number of persons across the Alzheimer's disease continuum.
    Alzheimers Dement. 2022 Jun 2. doi: 10.1002/alz.12694.
    PubMed     Abstract available


  8. SAWA M, Overk C, Becker A, Derse D, et al
    Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model.
    Alzheimers Dement. 2022;18:1203-1234.
    PubMed     Abstract available


  9. SYRJANEN JA, Campbell MR, Algeciras-Schimnich A, Vemuri P, et al
    Associations of amyloid and neurodegeneration plasma biomarkers with comorbidities.
    Alzheimers Dement. 2022;18:1128-1140.
    PubMed     Abstract available


  10. LIU L, Kwak H, Lawton TL, Jin SX, et al
    An ultra-sensitive immunoassay detects and quantifies soluble Abeta oligomers in human plasma.
    Alzheimers Dement. 2022;18:1186-1202.
    PubMed     Abstract available


  11. SANZ-BLASCO R, Ruiz-Sanchez de Leon JM, Avila-Villanueva M, Valenti-Soler M, et al
    Transition from mild cognitive impairment to normal cognition: Determining the predictors of reversion with multi-state Markov models.
    Alzheimers Dement. 2022;18:1177-1185.
    PubMed     Abstract available


    May 2022
  12. VOGLEIN J, Franzmeier N, Morris JC, Dieterich M, et al
    Patterns and implications of neurological examination findings in autosomal dominant Alzheimer disease.
    Alzheimers Dement. 2022 May 24. doi: 10.1002/alz.12684.
    PubMed     Abstract available


  13. HU Y, Zhang Y, Zhang H, Gao S, et al
    Mendelian randomization highlights causal association between genetically increased C-reactive protein levels and reduced Alzheimer's disease risk.
    Alzheimers Dement. 2022 May 22. doi: 10.1002/alz.12687.
    PubMed    


  14. LUO J, Thomassen JQ, Hegazy SH, Rasmussen IJ, et al
    Reply to "Mendelian randomization highlights causal association between genetically increased C-reactive protein levels and reduced Alzheimer's disease risk".
    Alzheimers Dement. 2022 May 22. doi: 10.1002/alz.12688.
    PubMed    


  15. ASHLEIGH T, Swerdlow RH, Beal MF
    The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis.
    Alzheimers Dement. 2022 May 6. doi: 10.1002/alz.12683.
    PubMed     Abstract available


  16. SEXTON C, Snyder H, Beher D, Boxer AL, et al
    Current directions in tau research: Highlights from Tau 2020.
    Alzheimers Dement. 2022;18:988-1007.
    PubMed     Abstract available


  17. IMBIMBO BP, Ippati S, Watling M, Balducci C, et al
    A critical appraisal of tau-targeting therapies for primary and secondary tauopathies.
    Alzheimers Dement. 2022;18:1008-1037.
    PubMed     Abstract available


  18. PERRY BL, McConnell WR, Coleman ME, Roth AR, et al
    Why the cognitive "fountain of youth" may be upstream: Pathways to dementia risk and resilience through social connectedness.
    Alzheimers Dement. 2022;18:934-941.
    PubMed     Abstract available


    April 2022
  19. CHANG R, Trushina E, Zhu K, Zaidi SSA, et al
    Predictive metabolic networks reveal sex- and APOE genotype-specific metabolic signatures and drivers for precision medicine in Alzheimer's disease.
    Alzheimers Dement. 2022 Apr 28. doi: 10.1002/alz.12675.
    PubMed     Abstract available


  20. PARK SY, Setiawan VW, White LR, Wu AH, et al
    Modifying effects of race and ethnicity and APOE on the association of physical activity with risk of Alzheimer's disease and related dementias.
    Alzheimers Dement. 2022 Apr 27. doi: 10.1002/alz.12677.
    PubMed     Abstract available


  21. JESSEN F, Wolfsgruber S, Kleineindam L, Spottke A, et al
    Subjective cognitive decline and stage 2 of Alzheimer disease in patients from memory centers.
    Alzheimers Dement. 2022 Apr 22. doi: 10.1002/alz.12674.
    PubMed     Abstract available


  22. QUAN L, Moreno-Gonzalez I, Xie Z, Gamez N, et al
    A near-infrared probe for detecting and interposing amyloid beta oligomerization in early Alzheimer's disease.
    Alzheimers Dement. 2022 Apr 18. doi: 10.1002/alz.12673.
    PubMed     Abstract available


  23. TJANDRA D, Migrino RQ, Giordani B, Wiens J, et al
    Use of blood pressure measurements extracted from the electronic health record in predicting Alzheimer's disease: A retrospective cohort study at two medical centers.
    Alzheimers Dement. 2022 Apr 16. doi: 10.1002/alz.12676.
    PubMed     Abstract available


  24. TA PARK VM, Meyer OL, Tsoh JY, Kanaya AM, et al
    The Collaborative Approach for Asian Americans and Pacific Islanders Research and Education (CARE): A recruitment registry for Alzheimer's disease and related dementias, aging, and caregiver-related research.
    Alzheimers Dement. 2022 Apr 14. doi: 10.1002/alz.12667.
    PubMed     Abstract available


  25. MARTINEZ AE, Weissberger G, Kuklenyik Z, He X, et al
    The small HDL particle hypothesis of Alzheimer's disease.
    Alzheimers Dement. 2022 Apr 13. doi: 10.1002/alz.12649.
    PubMed     Abstract available


  26. MIELKE MM, Aggarwal NT, Vila-Castelar C, Agarwal P, et al
    Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective.
    Alzheimers Dement. 2022 Apr 8. doi: 10.1002/alz.12662.
    PubMed     Abstract available


  27. WANG Y, Li M, Kazis LE, Xia W, et al
    Clinical outcomes of COVID-19 infection among patients with Alzheimer's disease or mild cognitive impairment.
    Alzheimers Dement. 2022 Apr 4. doi: 10.1002/alz.12665.
    PubMed     Abstract available


  28. LUCKETT PH, Chen C, Gordon BA, Wisch J, et al
    Biomarker clustering in autosomal dominant Alzheimer's disease.
    Alzheimers Dement. 2022 Apr 1. doi: 10.1002/alz.12661.
    PubMed     Abstract available


  29. NEUPANE A, Lenny B, Budde JP, Wang F, et al
    Replication study of AD-associated rare variants.
    Alzheimers Dement. 2022;18:858-862.
    PubMed    


  30. AKINYEMI RO, Yaria J, Ojagbemi A, Guerchet M, et al
    Dementia in Africa: Current evidence, knowledge gaps, and future directions.
    Alzheimers Dement. 2022;18:790-809.
    PubMed     Abstract available


  31. MURA T, Coley N, Amieva H, Berr C, et al
    Cognitive decline as an outcome and marker of progression toward dementia, in early preventive trials.
    Alzheimers Dement. 2022;18:676-687.
    PubMed     Abstract available


  32. LINDBOHM JV, Mars N, Walker KA, Singh-Manoux A, et al
    Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies.
    Alzheimers Dement. 2022;18:612-624.
    PubMed     Abstract available


  33. POURHADI N, Morch LS, Holm EA, Torp-Pedersen CT, et al
    Vaginal estrogen and association with dementia: A nationwide population-based study.
    Alzheimers Dement. 2022;18:625-634.
    PubMed     Abstract available


  34. MIELKE MM, Aakre JA, Algeciras-Schimnich A, Proctor NK, et al
    Comparison of CSF phosphorylated tau 181 and 217 for cognitive decline.
    Alzheimers Dement. 2022;18:602-611.
    PubMed     Abstract available


  35. CASANOVA R, Hsu FC, Barnard RT, Anderson AM, et al
    Comparing data-driven and hypothesis-driven MRI-based predictors of cognitive impairment in individuals from the Atherosclerosis Risk in Communities (ARIC) study.
    Alzheimers Dement. 2022;18:561-571.
    PubMed     Abstract available


  36. YANG HS, Zhang C, Carlyle BC, Zhen SY, et al
    Plasma IL-12/IFN-gamma axis predicts cognitive trajectories in cognitively unimpaired older adults.
    Alzheimers Dement. 2022;18:645-653.
    PubMed     Abstract available


    March 2022
  37. BRODY M, Agronin M, Herskowitz BJ, Bookheimer SY, et al
    Results and insights from a phase I clinical trial of Lomecel-B for Alzheimer's disease.
    Alzheimers Dement. 2022 Mar 31. doi: 10.1002/alz.12651.
    PubMed     Abstract available


  38. ZHANG X, Tong T, Chang A, Ang TFA, et al
    Midlife lipid and glucose levels are associated with Alzheimer's disease.
    Alzheimers Dement. 2022 Mar 23. doi: 10.1002/alz.12641.
    PubMed     Abstract available


  39. JACOBS HIL, Becker JA, Kwong K, Munera D, et al
    Waning locus coeruleus integrity precedes cortical tau accrual in preclinical autosomal dominant Alzheimer's disease.
    Alzheimers Dement. 2022 Mar 17. doi: 10.1002/alz.12656.
    PubMed     Abstract available


  40. LI P, Gao L, Yu L, Zheng X, et al
    Daytime napping and Alzheimer's dementia: A potential bidirectional relationship.
    Alzheimers Dement. 2022 Mar 17. doi: 10.1002/alz.12636.
    PubMed     Abstract available


  41. COE NB, White L, Oney M, Basu A, et al
    Public spending on acute and long-term care for Alzheimer's disease and related dementias.
    Alzheimers Dement. 2022 Mar 16. doi: 10.1002/alz.12657.
    PubMed     Abstract available



  42. 2022 Alzheimer's disease facts and figures.
    Alzheimers Dement. 2022 Mar 14. doi: 10.1002/alz.12638.
    PubMed     Abstract available


  43. LIU L, Lauro BM, He A, Lee H, et al
    Identification of the Abeta37/42 peptide ratio in CSF as an improved Abeta biomarker for Alzheimer's disease.
    Alzheimers Dement. 2022 Mar 12. doi: 10.1002/alz.12646.
    PubMed     Abstract available


  44. WINDER Z, Sudduth TL, Anderson S, Patel E, et al
    Examining the association between blood-based biomarkers and human post mortem neuropathology in the University of Kentucky Alzheimer's Disease Research Center autopsy cohort.
    Alzheimers Dement. 2022 Mar 10. doi: 10.1002/alz.12639.
    PubMed     Abstract available


  45. BREITNER JCS, Dodge HH, Khachaturian ZS, Khachaturian AS, et al
    "Exceptions that prove the rule"-Why have clinical trials failed to show efficacy of risk factor interventions suggested by observational studies of the dementia-Alzheimer's disease syndrome?
    Alzheimers Dement. 2022 Mar 4. doi: 10.1002/alz.12633.
    PubMed    



  46. Alzheimer's Association welcomes new Medical and Scientific Advisory Group members.
    Alzheimers Dement. 2022 Mar 4. doi: 10.1002/alz.12621.
    PubMed    


  47. O'BRYANT SE, Petersen M, Hall J, Johnson LA, et al
    Medical comorbidities and ethnicity impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and practice.
    Alzheimers Dement. 2022 Mar 2. doi: 10.1002/alz.12647.
    PubMed     Abstract available


  48. CONNOLLY K, Lehoux M, O'Rourke R, Assetta B, et al
    Potential role of chitinase-3-like protein 1 (CHI3L1/YKL-40) in neurodegeneration and Alzheimer's disease.
    Alzheimers Dement. 2022 Mar 2. doi: 10.1002/alz.12612.
    PubMed     Abstract available


  49. STOCKER H, Beyer L, Perna L, Rujescu D, et al
    Association of plasma biomarkers, p-tau181, glial fibrillary acidic protein, and neurofilament light, with intermediate and long-term clinical Alzheimer's disease risk: Results from a prospective cohort followed over 17 years.
    Alzheimers Dement. 2022 Mar 2. doi: 10.1002/alz.12614.
    PubMed     Abstract available


  50. CUMMINGS J, Salloway S
    Aducanumab: Appropriate use recommendations.
    Alzheimers Dement. 2022;18:531-533.
    PubMed    


  51. PETERSON A, Clapp J, Largent EA, Harkins K, et al
    What is paradoxical lucidity? The answer begins with its definition.
    Alzheimers Dement. 2022;18:513-521.
    PubMed     Abstract available


  52. BARIL AA, Beiser AS, Sanchez E, Mysliwiec V, et al
    Insomnia symptom severity and cognitive performance: Moderating role of APOE genotype.
    Alzheimers Dement. 2022;18:408-421.
    PubMed     Abstract available


    February 2022
  53. GIETL AF, Frisoni GB
    Early termination of pivotal trials in Alzheimer's disease-Preserving optimal value for participants and science.
    Alzheimers Dement. 2022 Feb 27. doi: 10.1002/alz.12605.
    PubMed     Abstract available


  54. KETCHUM FB, Chin NA, Grill J, Gleason CE, et al
    Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing.
    Alzheimers Dement. 2022 Feb 25. doi: 10.1002/alz.12620.
    PubMed     Abstract available


  55. ASHFORD MT, Raman R, Miller G, Donohue MC, et al
    Screening and enrollment of underrepresented ethnocultural and educational populations in the Alzheimer's Disease Neuroimaging Initiative (ADNI).
    Alzheimers Dement. 2022 Feb 25. doi: 10.1002/alz.12640.
    PubMed     Abstract available


  56. ZETTERBERG H
    Biofluid-based biomarkers for Alzheimer's disease-related pathologies: An update and synthesis of the literature.
    Alzheimers Dement. 2022 Feb 25. doi: 10.1002/alz.12618.
    PubMed     Abstract available


  57. XIONG C, Luo J, Schindler SE, Fagan AM, et al
    Racial differences in longitudinal Alzheimer's disease biomarkers among cognitively normal adults.
    Alzheimers Dement. 2022 Feb 25. doi: 10.1002/alz.12608.
    PubMed     Abstract available


  58. MONI F, Petersen ME, Zhang F, Lao PJ, et al
    Probing the proteome to explore potential correlates of increased Alzheimer's-related cerebrovascular disease in adults with Down syndrome.
    Alzheimers Dement. 2022 Feb 24. doi: 10.1002/alz.12627.
    PubMed     Abstract available


  59. LEVIN J, Voglein J, Quiroz YT, Bateman RJ, et al
    Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease.
    Alzheimers Dement. 2022 Feb 24. doi: 10.1002/alz.12624.
    PubMed     Abstract available


  60. QUIROZ YT, Solis M, Aranda MP, Arbaje AI, et al
    Addressing the disparities in dementia risk, early detection and care in Latino populations: Highlights from the second Latinos & Alzheimer's Symposium.
    Alzheimers Dement. 2022 Feb 24. doi: 10.1002/alz.12589.
    PubMed     Abstract available


  61. SEXTON C, Solis M, Aharon-Peretz J, Alexopoulos P, et al
    Alzheimer's disease research progress in the Mediterranean region: The Alzheimer's Association International Conference Satellite Symposium.
    Alzheimers Dement. 2022 Feb 20. doi: 10.1002/alz.12588.
    PubMed     Abstract available


  62. MECCA AP, O'Dell RS, Sharp ES, Banks ER, et al
    Synaptic density and cognitive performance in Alzheimer's disease: A PET imaging study with [(11) C]UCB-J.
    Alzheimers Dement. 2022 Feb 17. doi: 10.1002/alz.12582.
    PubMed     Abstract available


  63. SUCHY-DICEY A, Howard B, Longstreth WT Jr, Reiman EM, et al
    APOE genotype, hippocampus, and cognitive markers of Alzheimer's disease in American Indians: Data from the Strong Heart Study.
    Alzheimers Dement. 2022 Feb 10. doi: 10.1002/alz.12573.
    PubMed     Abstract available


  64. KRELL-ROESCH J, Rakusa M, Syrjanen JA, van Harten AC, et al
    Association between CSF biomarkers of Alzheimer's disease and neuropsychiatric symptoms: Mayo Clinic Study of Aging.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12557.
    PubMed     Abstract available


  65. CLAES C, England WE, Danhash EP, Kiani Shabestari S, et al
    The P522R protective variant of PLCG2 promotes the expression of antigen presentation genes by human microglia in an Alzheimer's disease mouse model.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12577.
    PubMed     Abstract available


  66. HU WT
    Reporting and social construction of race in Alzheimer's disease clinical trials.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12609.
    PubMed    


  67. ASTILLERO-LOPEZ V, Gonzalez-Rodriguez M, Villar-Conde S, Flores-Cuadrado A, et al
    Neurodegeneration and astrogliosis in the entorhinal cortex in Alzheimer's disease: Stereological layer-specific assessment and proteomic analysis.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12580.
    PubMed     Abstract available


  68. FLACH M, Leu C, Martinisi A, Skachokova Z, et al
    Trans-seeding of Alzheimer-related tau protein by a yeast prion.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12581.
    PubMed     Abstract available


  69. PRADOS MJ, Liu Y, Jun H, Lam J, et al
    Projecting the long-term societal value of a disease-modifying treatment for Alzheimer's disease in the United States.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12578.
    PubMed     Abstract available


  70. BABULAL GM, Franzen S, Abner EL, Smith JE, et al
    Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of race.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12611.
    PubMed    


  71. JUN GR, You Y, Zhu C, Meng G, et al
    Protein phosphatase 2A and complement component 4 are linked to the protective effect of APOE varepsilon2 for Alzheimer's disease.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12607.
    PubMed     Abstract available


  72. VARDARAJAN BN, Reyes-Dumeyer D, Piriz AL, Lantigua RA, et al
    Progranulin mutations in clinical and neuropathological Alzheimer's disease.
    Alzheimers Dement. 2022 Feb 9. doi: 10.1002/alz.12567.
    PubMed     Abstract available


  73. REIKEN S, Sittenfeld L, Dridi H, Liu Y, et al
    Alzheimer's-like signaling in brains of COVID-19 patients.
    Alzheimers Dement. 2022 Feb 3. doi: 10.1002/alz.12558.
    PubMed     Abstract available


  74. RUTHIRAKUHAN M, Ismail Z, Herrmann N, Gallagher D, et al
    Mild behavioral impairment is associated with progression to Alzheimer's disease: A clinicopathological study.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12519.
    PubMed     Abstract available


  75. REIMAN EM, Mattke S, Kordower JH, Khachaturian ZS, et al
    Developing a pathway to support the appropriate, affordable, and widespread use of effective Alzheimer's prevention drugs.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12533.
    PubMed    



  76. Applications being accepted for the Alzheimer's Association Interdisciplinary Summer Research Institute.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12585.
    PubMed    


  77. VILA-CASTELAR C, Tariot PN, Sink KM, Clayton D, et al
    Sex differences in cognitive resilience in preclinical autosomal-dominant Alzheimer's disease carriers and non-carriers: Baseline findings from the API ADAD Colombia Trial.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12552.
    PubMed     Abstract available


  78. WAGNER M, Wilson RS, Leurgans SE, Boyle PA, et al
    Quantifying longitudinal cognitive resilience to Alzheimer's disease and other neuropathologies.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12576.
    PubMed     Abstract available


  79. ERATNE D, Loi SM, Li QX, Stehmann C, et al
    Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings.
    Alzheimers Dement. 2022 Feb 1. doi: 10.1002/alz.12549.
    PubMed     Abstract available


  80. O'BRYANT S, Petersen M, Hall J, Johnson L, et al
    Characterizing plasma NfL in a community-dwelling multi-ethnic cohort: Results from the HABLE study.
    Alzheimers Dement. 2022;18:240-250.
    PubMed     Abstract available


  81. NAUEN DW, Troncoso JC
    Amyloid-beta is present in human lymph nodes and greatly enriched in those of the cervical region.
    Alzheimers Dement. 2022;18:205-210.
    PubMed     Abstract available


  82. KREISL WC, Lao PJ, Johnson A, Tomljanovic Z, et al
    Patterns of tau pathology identified with (18) F-MK-6240 PET imaging.
    Alzheimers Dement. 2022;18:272-282.
    PubMed     Abstract available


  83. SCHMUTTE T, Olfson M, Maust DT, Xie M, et al
    Suicide risk in first year after dementia diagnosis in older adults.
    Alzheimers Dement. 2022;18:262-271.
    PubMed     Abstract available


    January 2022
  84. CALDWELL AB, Liu Q, Zhang C, Schroth GP, et al
    Endotype reversal as a novel strategy for screening drugs targeting familial Alzheimer's disease.
    Alzheimers Dement. 2022 Jan 27. doi: 10.1002/alz.12553.
    PubMed     Abstract available


  85. WANG T, Huynh K, Giles C, Mellett NA, et al
    APOE epsilon2 resilience for Alzheimer's disease is mediated by plasma lipid species: Analysis of three independent cohort studies.
    Alzheimers Dement. 2022 Jan 25. doi: 10.1002/alz.12538.
    PubMed     Abstract available


  86. JORDA-SIQUIER T, Petrel M, Kouskoff V, Smailovic U, et al
    APP accumulates with presynaptic proteins around amyloid plaques: A role for presynaptic mechanisms in Alzheimer's disease?
    Alzheimers Dement. 2022 Jan 25. doi: 10.1002/alz.12546.
    PubMed     Abstract available


  87. FRONTERA JA, Boutajangout A, Masurkar AV, Betensky RA, et al
    Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia.
    Alzheimers Dement. 2022 Jan 13. doi: 10.1002/alz.12556.
    PubMed     Abstract available


  88. YAO J, Liu Y, Sun B, Zhan X, et al
    Increased RyR2 open probability induces neuronal hyperactivity and memory loss with or without Alzheimer's disease-causing gene mutations.
    Alzheimers Dement. 2022 Jan 5. doi: 10.1002/alz.12543.
    PubMed     Abstract available


  89. NAZARIAN A, Loika Y, He L, Culminskaya I, et al
    Genome-wide analysis identified abundant genetic modulators of contributions of the apolipoprotein E alleles to Alzheimer's disease risk.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12540.
    PubMed     Abstract available


  90. REYES-DUMEYER D, Faber K, Vardarajan B, Goate A, et al
    The National Institute on Aging Late-Onset Alzheimer's Disease Family Based Study: A resource for genetic discovery.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12514.
    PubMed     Abstract available


  91. QIU S, Hu Y, Cheng L
    BIN1 rs744373 located in enhancers of brain tissues upregulates BIN1 mRNA expression, thereby leading to Alzheimer's disease.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12548.
    PubMed    


  92. ZAMOLODCHIKOV D, Duffield M, Macdonald LE, Alessandri-Haber N, et al
    Accumulation of high molecular weight kininogen in the brains of Alzheimer's disease patients may affect microglial function by altering phagocytosis and lysosomal cathepsin activity.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12531.
    PubMed     Abstract available



  93. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring announces new editor-in-chief for open access, peer reviewed journal.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12517.
    PubMed    


  94. KETCHUM FB
    Solomon Carter Fuller: Alzheimer's contemporary and American pioneer.
    Alzheimers Dement. 2022 Jan 3. doi: 10.1002/alz.12551.
    PubMed    


  95. JAKEL L, De Kort AM, Klijn CJM, Schreuder FHBM, et al
    Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis.
    Alzheimers Dement. 2022;18:10-28.
    PubMed     Abstract available


  96. ZHAO Y, Kuca K, Wu W, Wang X, et al
    Hypothesis: JNK signaling is a therapeutic target of neurodegenerative diseases.
    Alzheimers Dement. 2022;18:152-158.
    PubMed     Abstract available


  97. BUTT OH, Meeker KL, Wisch JK, Schindler SE, et al
    Network dysfunction in cognitively normal APOE epsilon4 carriers is related to subclinical tau.
    Alzheimers Dement. 2022;18:116-126.
    PubMed     Abstract available


  98. VOGT NM, Hunt JFV, Adluru N, Ma Y, et al
    Interaction of amyloid and tau on cortical microstructure in cognitively unimpaired adults.
    Alzheimers Dement. 2022;18:65-76.
    PubMed     Abstract available


    December 2021
  99. DELABY C, Teunissen CE, Blennow K, Alcolea D, et al
    Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview.
    Alzheimers Dement. 2021 Dec 22. doi: 10.1002/alz.12545.
    PubMed     Abstract available


  100. MING C, Wang M, Wang Q, Neff R, et al
    Whole genome sequencing-based copy number variations reveal novel pathways and targets in Alzheimer's disease.
    Alzheimers Dement. 2021 Dec 17. doi: 10.1002/alz.12507.
    PubMed     Abstract available


  101. HAWKINSON TR, Clarke HA, Young LEA, Conroy LR, et al
    In situ spatial glycomic imaging of mouse and human Alzheimer's disease brains.
    Alzheimers Dement. 2021 Dec 15. doi: 10.1002/alz.12523.
    PubMed     Abstract available


  102. LIM U, Wang S, Park SY, Bogumil D, et al
    Risk of Alzheimer's disease and related dementia by sex and race/ethnicity: The Multiethnic Cohort Study.
    Alzheimers Dement. 2021 Dec 9. doi: 10.1002/alz.12528.
    PubMed     Abstract available


  103. GORDON MN, Heneka MT, Le Page LM, Limberger C, et al
    Impact of COVID-19 on the Onset and Progression of Alzheimer's Disease and Related Dementias: A Roadmap for Future Research.
    Alzheimers Dement. 2021 Dec 7. doi: 10.1002/alz.12488.
    PubMed     Abstract available


  104. DE KORT AM, Kuiperij HB, Kersten I, Versleijen AAM, et al
    Normal cerebrospinal fluid concentrations of PDGFRbeta in patients with cerebral amyloid angiopathy and Alzheimer's disease.
    Alzheimers Dement. 2021 Dec 7. doi: 10.1002/alz.12506.
    PubMed     Abstract available


  105. SILVERMAN W, Krinsky-McHale SJ, Zigman WB, Schupf N, et al
    Adults with Down syndrome in randomized clinical trials targeting prevention of Alzheimer's disease.
    Alzheimers Dement. 2021 Dec 7. doi: 10.1002/alz.12520.
    PubMed     Abstract available


  106. SAROJA SR, Sharma A, Hof PR, Pereira AC, et al
    Differential expression of tau species and the association with cognitive decline and synaptic loss in Alzheimer's disease.
    Alzheimers Dement. 2021 Dec 7. doi: 10.1002/alz.12518.
    PubMed     Abstract available


  107. GLEASON CE, Zuelsdorff M, Gooding DC, Kind AJH, et al
    Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence.
    Alzheimers Dement. 2021 Dec 6. doi: 10.1002/alz.12511.
    PubMed     Abstract available


  108. HAEGER A, Bottlaender M, Lagarde J, Porciuncula Baptista R, et al
    What can 7T sodium MRI tell us about cellular energy depletion and neurotransmission in Alzheimer's disease?
    Alzheimers Dement. 2021 Dec 2. doi: 10.1002/alz.12501.
    PubMed     Abstract available



  109. AAIC 2021: The promise of Alzheimer's research.
    Alzheimers Dement. 2021 Dec 2. doi: 10.1002/alz.12500.
    PubMed    


  110. FRANK B, Ally M, Brekke B, Zetterberg H, et al
    Plasma p-tau181 shows stronger network association to Alzheimer's disease dementia than neurofilament light and total tau.
    Alzheimers Dement. 2021 Dec 2. doi: 10.1002/alz.12508.
    PubMed     Abstract available


  111. STATHAS S, Alvarez VE, Xia W, Nicks R, et al
    Tau phosphorylation sites serine202 and serine396 are differently altered in chronic traumatic encephalopathy and Alzheimer's disease.
    Alzheimers Dement. 2021 Dec 2. doi: 10.1002/alz.12502.
    PubMed     Abstract available


  112. BUCKLES VD, Xiong C, Bateman RJ, Hassenstab J, et al
    Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease.
    Alzheimers Dement. 2021 Dec 2. doi: 10.1002/alz.12505.
    PubMed     Abstract available


  113. STRINGER C, Smithroat N, Samus QM, Johnston D, et al
    From research to realization: How a Texas health plan implemented an academic model of care for Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 8:e054058.
    PubMed     Abstract available


  114. MENENGIC KN, Yeldan I, Cinar N, Sahiner TA, et al
    Effectiveness of home-based telerehabilitation in mild to moderate Alzheimer's disease: A randomised controlled study.
    Alzheimers Dement. 2021;17 Suppl 8:e053406.
    PubMed     Abstract available


  115. ASCHETTINO LA, Labyak CA, Sealey-Potts C
    Nutritional treatments for Alzheimer's disease: A narrative review.
    Alzheimers Dement. 2021;17 Suppl 8:e053172.
    PubMed     Abstract available


  116. LEE JH, Kim DY, Kim MG, Kang H, et al
    Preventing cognitive decline in older adults with mild cognitive impairment using integrated Korean and Western treatments: Initial results.
    Alzheimers Dement. 2021;17 Suppl 8:e052545.
    PubMed     Abstract available


  117. GELDMACHER DS, Christopher R, Anderson M, Bero AW, et al
    Development of a site readiness framework to improve health system preparedness for potential new Alzheimer's disease therapies.
    Alzheimers Dement. 2021;17 Suppl 8:e057672.
    PubMed     Abstract available


  118. KEELY AJ
    The first female engineer at General Motor's descent into Alzheimer's with sundowners: A daughter's scholarly research and case study as caregiver.
    Alzheimers Dement. 2021;17 Suppl 8:e050143.
    PubMed     Abstract available


  119. FLATT JD, Pollock K, Lee R, Song Y, et al
    Feasibility of the Savvy Caregiver program for care providers of LGBTQ adults living with Alzheimer's disease and related dementias.
    Alzheimers Dement. 2021;17 Suppl 8:e055633.
    PubMed     Abstract available


  120. MILLER DR, Jasuja G, Davila HW, Palnati M, et al
    Care processes related to clinical detection of Alzheimer's disease in the U.S. Veterans Affairs Health Care System.
    Alzheimers Dement. 2021;17 Suppl 8:e054149.
    PubMed     Abstract available


  121. MAKSIMOVICH IV
    Stimulation of cerebral angiogenesis and neurogenesis with transcatheter intracerebral laser photobiomodulation therapy during dementia in patients with Alzheimer's and Binswanger's disease.
    Alzheimers Dement. 2021;17 Suppl 8:e054945.
    PubMed     Abstract available


  122. GONZALEZ A, Camila C, Maccioni RB
    Alzheimer's disease: A potential diabetes type 3.
    Alzheimers Dement. 2021;17 Suppl 2:e058533.
    PubMed     Abstract available


  123. MOYLAN C, Cao TV, Huynh QS, Pratap A, et al
    Exercise-Induced Alterations in TrkB expression in the 5XFAD Mouse Model of Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058733.
    PubMed     Abstract available


  124. GAITAN JM, Dubal DB, Okonkwo OC
    Circulating klotho is elevated in cerebrospinal fluid, but not serum, among KLOTHO KL-VS allele carriers at risk for Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058612.
    PubMed     Abstract available


  125. COULON A, Mendes T, Kilinc D, Dumont J, et al
    High-content screening of Alzheimer's disease genetic risk factors based on synaptic density analysis.
    Alzheimers Dement. 2021;17 Suppl 2:e058660.
    PubMed     Abstract available


  126. TSAI AP, Lin PB, Dong C, Moutinho M, et al
    Impact of PLCG2 expression on Microglial Biology and Disease Pathogenesis in Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058740.
    PubMed     Abstract available


  127. HUANG CW, Hart GW
    Decreased O-GlcNAcylation and mitochondrial dysfunction are involving in low glucose induced Alzheimer's disease-like phenotype in induced pluripotent stem cell-derived neurons.
    Alzheimers Dement. 2021;17 Suppl 2:e058620.
    PubMed     Abstract available


  128. BRACH TL, Gaitan JM, Okonkwo OC
    Effect of Aerobic Exercise Training on Mood and Cognition in Adults at Risk for Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058523.
    PubMed     Abstract available


  129. LIN PB, Tsai AP, Nho K, Lamb BT, et al
    INPP5D regulates the amyloid pathology in Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058724.
    PubMed     Abstract available


  130. KUMAR A, Doran E, Martini AC, Head E, et al
    CAA and related co-morbidities in Down syndrome and Alzheimer disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058726.
    PubMed     Abstract available


  131. TEMITOPE SR
    The role of lycopene on the hippocampus of rat model of lipopolysaccharide-induced Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058528.
    PubMed     Abstract available


  132. YEATES C, Sarkar A, Deshpande P, Kango-Singh M, et al
    A Two-Clone approach to study signaling interactions among neuronal cells in a pre-clinical Alzheimer's Disease model.
    Alzheimers Dement. 2021;17 Suppl 2:e058690.
    PubMed     Abstract available


  133. GOMEZ J JR, Villegas-Lanau CA, Mesa A Sr
    Colocalization of the beta amyloid peptide with bacteria in postmortem brain tissue of patients with familial Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058692.
    PubMed     Abstract available


  134. SUNG K, Yang F, Noble W, Jimenez-Sanchez M, et al
    Investigating the non-cell autonomous role of glial chaperones in Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058572.
    PubMed     Abstract available


  135. GOMEZ J JR, Villegas-Lanau CA, Mesa A Sr
    Human Herpesvirus detection and identification in postmortem brain tissue of patients with Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058693.
    PubMed     Abstract available


  136. SCHRAUBEN M, Smith AR, Washer S, Dempster E, et al
    Investigating epigenetic loci implicated in Alzheimer's disease via the CRISPR-Cas9 system.
    Alzheimers Dement. 2021;17 Suppl 2:e058573.
    PubMed     Abstract available


  137. TALIYAN R, Kakoty V, Kc S, Kumari S, et al
    Fibroblast Growth Factor 21 and Autophagy Modulation Ameliorates Amyloid beta-Induced Alzheimer Disease Pathology in Rats.
    Alzheimers Dement. 2021;17 Suppl 2:e058695.
    PubMed     Abstract available


  138. YANG F, Sung K, Sanchez MJ
    Investigating the secretion of small heat shock proteins in reactive astrocytes in Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058498.
    PubMed     Abstract available


  139. ROSENE MJ, Hsu S, Martinez R, Norton J, et al
    Defining the role of PLD3 in Alzheimer's disease pathology.
    Alzheimers Dement. 2021;17 Suppl 2:e058730.
    PubMed     Abstract available


  140. TREMBLAY JP, Tremblay G, Guyon A, Joel R, et al
    Insertion of the Icelandic mutation (A673T) in the APP gene using the CRISPR/Cas9 base editing and Prime editing technologies, a preventive treatment for Alzheimer?
    Alzheimers Dement. 2021;17 Suppl 2:e058710.
    PubMed     Abstract available


  141. CHEN J, Samoylova NG, Cummings MG
    TOMM40, a risk gene for Alzheimer's disease, is upregulated during proinflammatory response.
    Alzheimers Dement. 2021;17 Suppl 2:e058711.
    PubMed     Abstract available


  142. MCARDLE CJ, Niere F, Uneri A, Raab-Graham KF, et al
    Alterations in dendritic GABAB receptor expression in an Alzheimer's disease mouse model.
    Alzheimers Dement. 2021;17 Suppl 2:e058557.
    PubMed     Abstract available


  143. DESHPANDE P, Chen CY, Yeates C, Chen CH, et al
    miR-277 targets hid to ameliorate Abeta42-mediated neurodegeneration in Drosophila eye model of Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058678.
    PubMed     Abstract available


  144. ZHAO P, Mangleburg CG, Al-Ramahi I, Botas J, et al
    Systems genetic dissection of Alzheimer's disease brain gene expression networks.
    Alzheimers Dement. 2021;17 Suppl 2:e058716.
    PubMed     Abstract available


  145. MUMFORD P, Noy S, Tybulewicz VL, Fisher E, et al
    Preclinical modelling in the mouse of altered neuroinflammation in Alzheimer's disease - Down syndrome.
    Alzheimers Dement. 2021;17 Suppl 2:e058441.
    PubMed     Abstract available


  146. TIPTON AE, George J, Ratner M, Farb D, et al
    Data from single nuclei RNA-sequencing reveals a prodromal gene network response in excitatory neurons of a humanized rat Alzheimer's disease model.
    Alzheimers Dement. 2021;17 Suppl 2:e058589.
    PubMed     Abstract available


  147. TAYLOR AL, Davis DE Jr, Codreanu SG, Harrison FE, et al
    Targeted and untargeted mass spectrometry reveals impact of high fat diet on peripheral amino acid regulation in a mouse model of Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058428.
    PubMed     Abstract available


  148. ROSOLEN SA
    Exercise-induced metabolic changes in astrocytes in the 5xFAD mouse model of Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 2:e058627.
    PubMed     Abstract available


  149. SRIVASTAV A, Mohideen SS
    Intestinal microbial dysbiosis induced tau accumulation establishes a gut-brain correlation for pathology Alzheimer's disease in Drosophila melanogaster.
    Alzheimers Dement. 2021;17 Suppl 2:e058708.
    PubMed     Abstract available


  150. HERSH SW, You Y, Aslebagh R, Shaffer SA, et al
    Alzheimer's disease associated AKAP9 I2558M mutation alters posttranslational modification and interactome of tau and cellular functions in CRISPR-edited human neuronal cells.
    Alzheimers Dement. 2021;17 Suppl 2:e058592.
    PubMed     Abstract available


  151. PRATER KE, Green KJ, Chiou KL, Smith CL, et al
    Microglia subtype transcriptomes differ between Alzheimer Disease and control human postmortem brain samples.
    Alzheimers Dement. 2021;17 Suppl 2:e058474.
    PubMed     Abstract available


  152. CZAPLICKI AM, Gaitan JM, Bendlin BB, Johnson SC, et al
    The Interaction between Ventricle to Brain Ratio and Serum Klotho on Cognition in Older Adults at Risk for Alzheimer's Disease.
    Alzheimers Dement. 2021;17 Suppl 12:e058632.
    PubMed     Abstract available


  153. BABATOPE EY, Acosta-Franco JA, Garcia-Vazquez MS, Ramirez-Acosta AA, et al
    Applying a deep learning approach focusing on spatiotemporal features in early diagnosis of Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 12:e058635.
    PubMed     Abstract available


  154. MCINTYRE CC, Okonkwo OC, Gaitan JM, Bendlin BB, et al
    Effect of insulin resistance on the association between cardiorespiratory fitness and cognition in adults at risk for Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 12:e058683.
    PubMed     Abstract available


  155. WANG RP, Leung WK, Goto T, Ho JY, et al
    IL-1 beta and TNF-alpha play an essential role in modulating the risk of both periodontitis and Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 12:e058464.
    PubMed     Abstract available


  156. MEMUDU AE, Waziri RJ
    An investigative study to demonstrate the link between combined intake of marijuana and codeine in Alzheimer's disease pathology.
    Alzheimers Dement. 2021;17 Suppl 12:e058465.
    PubMed     Abstract available


  157. RISHITHA N, Muthuraman A
    Therapeutic investigation of alpha napthoflavone in the intracerebroventricular injection of L-cysteine induced vascular dementia in rats.
    Alzheimers Dement. 2021;17 Suppl 12:e058344.
    PubMed     Abstract available


  158. ABDULKADIR TS, Isa AS, Dawud FA, Ayo JO, et al
    Effect of taurine and camel milk on amyloid beta peptide concentration and oxidative stress changes in aluminium chloride-induced Alzheimer's disease rats.
    Alzheimers Dement. 2021;17 Suppl 12:e058642.
    PubMed     Abstract available


  159. OKHUEVBIE DO, Awolaja S, Balogun Z
    Evaluation of the effect of Donepezil hydrochloride on Ethanol-induced hippocampal damage.
    Alzheimers Dement. 2021;17 Suppl 12:e058353.
    PubMed     Abstract available


  160. K C S, Kakoty VK, Taliyan R
    Development and Validation of PEG-PCL Based Nanoformulation of Rosiglitazone and Evaluation of its Brain Selectivity in Mice Model of Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 12:e058674.
    PubMed     Abstract available


  161. TORT-MERINO A, Tarnanas I, Bugler M, Harms R, et al
    ALTOIDA-iADL for the diagnosis of Mild Cognitive Impairment and early Alzheimer's disease.
    Alzheimers Dement. 2021;17 Suppl 12:e057982.
    PubMed     Abstract available


  162. ROWE EM, Louadi S, Koch E, Kuhlmann N, et al
    A Month in Neurodegenerative Disease Research (AMiNDR): The evolution of an open-access podcast series for Alzheimer's researchers.
    Alzheimers Dement. 2021;17 Suppl 11:e053287.
    PubMed     Abstract available


  163. YUAN F, Lopez RP, Crane M, Montgomery A, et al
    Feasibility and acceptance of robotic care of Alzheimer's disease and related dementia.
    Alzheimers Dement. 2021;17 Suppl 11:e052585.
    PubMed     Abstract available


  164. KUHNEL L, Bouteloup V, Lespinasse J, Chene G, et al
    Personalized prediction of progression in pre-dementia patients based on individual biomarker profile: A development and validation study.
    Alzheimers Dement. 2021;17:1938-1949.
    PubMed     Abstract available


  165. GOLD BT, Shao X, Sudduth TL, Jicha GA, et al
    Water exchange rate across the blood-brain barrier is associated with CSF amyloid-beta 42 in healthy older adults.
    Alzheimers Dement. 2021;17:2020-2029.
    PubMed     Abstract available


  166. XU Y, Chen Z, Wey HY, Liang Y, et al
    Molecular imaging of NAD(+) -dependent deacetylase SIRT1 in the brain.
    Alzheimers Dement. 2021;17:1988-1997.
    PubMed     Abstract available


    November 2021
  167. VERBERK IMW, Misdorp EO, Koelewijn J, Ball AJ, et al
    Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group.
    Alzheimers Dement. 2021 Nov 29. doi: 10.1002/alz.12510.
    PubMed     Abstract available


  168. MURCHISON AG
    Hypothesis: Modulation of microglial phenotype in Alzheimer's disease drives neurodegeneration.
    Alzheimers Dement. 2021 Nov 17. doi: 10.1002/alz.12503.
    PubMed     Abstract available


  169. JIA L, Yang J, Zhu M, Pang Y, et al
    A metabolite panel that differentiates Alzheimer's disease from other dementia types.
    Alzheimers Dement. 2021 Nov 17. doi: 10.1002/alz.12484.
    PubMed     Abstract available


  170. WEINTRAUB S, Karpouzian-Rogers T, Peipert JD, Nowinski C, et al
    ARMADA: Assessing reliable measurement in Alzheimer's disease and cognitive aging project methods.
    Alzheimers Dement. 2021 Nov 17. doi: 10.1002/alz.12497.
    PubMed     Abstract available


  171. JUTKOWITZ E, Halladay C, Tsai J, Hooshyar D, et al
    Prevalence of Alzheimer's disease and related dementias among veterans experiencing housing insecurity.
    Alzheimers Dement. 2021 Nov 10. doi: 10.1002/alz.12476.
    PubMed     Abstract available


  172. HORGUSLUOGLU E, Neff R, Song WM, Wang M, et al
    Integrative metabolomics-genomics approach reveals key metabolic pathways and regulators of Alzheimer's disease.
    Alzheimers Dement. 2021 Nov 10. doi: 10.1002/alz.12468.
    PubMed     Abstract available


  173. BOADA M, Lopez OL, Olazaran J, Nunez L, et al
    Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.
    Alzheimers Dement. 2021 Nov 2. doi: 10.1002/alz.12477.
    PubMed     Abstract available


  174. EZZATI A, Abdulkadir A, Jack CR Jr, Thompson PM, et al
    Predictive value of ATN biomarker profiles in estimating disease progression in Alzheimer's disease dementia.
    Alzheimers Dement. 2021;17:1855-1867.
    PubMed     Abstract available


  175. TAHIRA AC, Verjovski-Almeida S, Ferreira ST
    Dementia is an age-independent risk factor for severity and death in COVID-19 inpatients.
    Alzheimers Dement. 2021;17:1818-1831.
    PubMed     Abstract available


    October 2021
  176. TOSUN D, Demir Z, Veitch DP, Weintraub D, et al
    Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum.
    Alzheimers Dement. 2021 Oct 14. doi: 10.1002/alz.12480.
    PubMed     Abstract available


  177. MEYERS EA, Amouyel P, Bovenkamp DE, Carrillo MC, et al
    Commentary: Global Alzheimer's disease and Alzheimer's disease related dementia research funding organizations support and engage the research community throughout the COVID-19 pandemic.
    Alzheimers Dement. 2021 Oct 1. doi: 10.1002/alz.12472.
    PubMed     Abstract available



  178. Alzheimer's Disease Interventions: Implications of therapeutic promises amidst questions and doubts about clinically meaningful outcomes.
    Alzheimers Dement. 2021;17:1591-1594.
    PubMed    


  179. DE MAULEON A, Ismail Z, Rosenberg P, Miller D, et al
    Agitation in Alzheimer's disease: Novel outcome measures reflecting the International Psychogeriatric Association (IPA) agitation criteria.
    Alzheimers Dement. 2021;17:1687-1697.
    PubMed     Abstract available


  180. DAMOTTE V, van der Lee SJ, Chouraki V, Grenier-Boley B, et al
    Plasma amyloid beta levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome-wide association study in over 12,000 non-demented participants.
    Alzheimers Dement. 2021;17:1663-1674.
    PubMed     Abstract available


  181. BANGEN KJ, Thomas KR, Weigand AJ, Edmonds EC, et al
    Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively-defined subtle cognitive decline and MCI.
    Alzheimers Dement. 2021;17:1756-1762.
    PubMed     Abstract available


  182. MEZ J, Alosco ML, Daneshvar DH, Saltiel N, et al
    Validity of the 2014 traumatic encephalopathy syndrome criteria for CTE pathology.
    Alzheimers Dement. 2021;17:1709-1724.
    PubMed     Abstract available


  183. GALVIN JE, Chrisphonte S, Cohen I, Greenfield KK, et al
    Characterization of dementia with Lewy bodies (DLB) and mild cognitive impairment using the Lewy body dementia module (LBD-MOD).
    Alzheimers Dement. 2021;17:1675-1686.
    PubMed     Abstract available


  184. YANG C, Li X, Zhang J, Chen Y, et al
    Early prevention of cognitive impairment in the community population: The Beijing Aging Brain Rejuvenation Initiative.
    Alzheimers Dement. 2021;17:1610-1618.
    PubMed     Abstract available


    September 2021
  185. FRANZEN S, Smith JE, van den Berg E, Rivera Mindt M, et al
    Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria.
    Alzheimers Dement. 2021 Sep 30. doi: 10.1002/alz.12433.
    PubMed     Abstract available


  186. PICARD C, Nilsson N, Labonte A, Auld D, et al
    Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 29. doi: 10.1002/alz.12442.
    PubMed     Abstract available


  187. JICHA GA, Abner EL, Arnold SE, Carrillo MC, et al
    Committee on High-quality Alzheimer's Disease Studies (CHADS) consensus report.
    Alzheimers Dement. 2021 Sep 29. doi: 10.1002/alz.12461.
    PubMed     Abstract available


  188. CUMMINGS JL, Goldman DP, Simmons-Stern NR, Ponton E, et al
    The costs of developing treatments for Alzheimer's disease: A retrospective exploration.
    Alzheimers Dement. 2021 Sep 28. doi: 10.1002/alz.12450.
    PubMed     Abstract available


  189. VEITCH DP, Weiner MW, Aisen PS, Beckett LA, et al
    Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 28. doi: 10.1002/alz.12422.
    PubMed     Abstract available


  190. WANG C, Wang Z, Xie B, Shi X, et al
    Binaural processing deficit and cognitive impairment in Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 27. doi: 10.1002/alz.12464.
    PubMed     Abstract available


  191. MATTKE S, Hanson M
    Expected wait times for access to a disease-modifying Alzheimer's treatment in the United States.
    Alzheimers Dement. 2021 Sep 27. doi: 10.1002/alz.12470.
    PubMed     Abstract available


  192. PHILLIPS JS, Nitchie FJ 4th, Da Re F, Olm CA, et al
    Rates of longitudinal change in (18) F-flortaucipir PET vary by brain region, cognitive impairment, and age in atypical Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 13. doi: 10.1002/alz.12456.
    PubMed     Abstract available


  193. ZHANG L, Du Rietz E, Kuja-Halkola R, Dobrosavljevic M, et al
    Attention-deficit/hyperactivity disorder and Alzheimer's disease and any dementia: A multi-generation cohort study in Sweden.
    Alzheimers Dement. 2021 Sep 9. doi: 10.1002/alz.12462.
    PubMed     Abstract available


  194. CHATTERJEE P, Pedrini S, Ashton NJ, Tegg M, et al
    Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 8. doi: 10.1002/alz.12447.
    PubMed     Abstract available


  195. MARTERSTECK A, Sridhar J, Coventry C, Weintraub S, et al
    Relationships among tau burden, atrophy, age, and naming in the aphasic variant of Alzheimer's disease.
    Alzheimers Dement. 2021 Sep 8. doi: 10.1002/alz.12445.
    PubMed     Abstract available


  196. LOGSDON AF, Francis KL, Richardson NE, Hu SJ, et al
    Decoding perineuronal net glycan sulfation patterns in the Alzheimer's disease brain.
    Alzheimers Dement. 2021 Sep 5. doi: 10.1002/alz.12451.
    PubMed     Abstract available


  197. MA Y, Yu L, Olah M, Smith R, et al
    Epigenomic features related to microglia are associated with attenuated effect of APOE epsilon4 on Alzheimer's disease risk in humans.
    Alzheimers Dement. 2021 Sep 5. doi: 10.1002/alz.12425.
    PubMed     Abstract available


  198. REN RJ, Huang Q, Xu G, Gu K, et al
    Association between Alzheimer's disease and risk of cancer: A retrospective cohort study in Shanghai, China.
    Alzheimers Dement. 2021 Sep 5. doi: 10.1002/alz.12436.
    PubMed     Abstract available


  199. PEGUEROLES J, Montal V, Bejanin A, Vilaplana E, et al
    AMYQ: An index to standardize quantitative amyloid load across PET tracers.
    Alzheimers Dement. 2021;17:1499-1508.
    PubMed     Abstract available


    August 2021
  200. GHAZARIAN AL, Haim T, Sauma S, Katiyar P, et al
    National Institute on Aging seed funding enables Alzheimer's disease startups to reach key value inflection points.
    Alzheimers Dement. 2021 Aug 10. doi: 10.1002/alz.12392.
    PubMed     Abstract available


  201. WANG Q, Davis PB, Gurney ME, Xu R, et al
    COVID-19 and dementia: Analyses of risk, disparity, and outcomes from electronic health records in the US.
    Alzheimers Dement. 2021;17:1297-1306.
    PubMed     Abstract available


  202. PIERUCCINI-FARIA F, Black SE, Masellis M, Smith EE, et al
    Gait variability across neurodegenerative and cognitive disorders: Results from the Canadian Consortium of Neurodegeneration in Aging (CCNA) and the Gait and Brain Study.
    Alzheimers Dement. 2021;17:1317-1328.
    PubMed     Abstract available


  203. BAUCKNEHT M, Chincarini A, Brendel M, Rominger A, et al
    Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A European-DLB consortium project.
    Alzheimers Dement. 2021;17:1277-1286.
    PubMed     Abstract available


  204. GIANATTASIO KZ, Bennett EE, Wei J, Mehrotra ML, et al
    Generalizability of findings from a clinical sample to a community-based sample: A comparison of ADNI and ARIC.
    Alzheimers Dement. 2021;17:1265-1276.
    PubMed     Abstract available


    July 2021
  205. GARNIER-CRUSSARD A, Bougacha S, Wirth M, Dautricourt S, et al
    White matter hyperintensity topography in Alzheimer's disease and links to cognition.
    Alzheimers Dement. 2021 Jul 28. doi: 10.1002/alz.12410.
    PubMed     Abstract available


  206. BOADA M, Rodrigo A, Jessen F, Wimblad B, et al
    Complementary pre-screening strategies to uncover hidden prodromal and mild Alzheimer's disease: Results from the MOPEAD project.
    Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12441.
    PubMed     Abstract available


  207. HOSCHEIDT S, Sanderlin AH, Baker LD, Jung Y, et al
    Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid-life: A randomized trial.
    Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12421.
    PubMed     Abstract available


  208. VAN HARTEN AC, Wiste HJ, Weigand SD, Mielke MM, et al
    Detection of Alzheimer's disease amyloid beta 1-42, p-tau, and t-tau assays.
    Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12406.
    PubMed     Abstract available


  209. KULMINSKI AM, Philipp I, Loika Y, He L, et al
    Protective association of the epsilon2/epsilon3 heterozygote with Alzheimer's disease is strengthened by TOMM40-APOE variants in men.
    Alzheimers Dement. 2021 Jul 26. doi: 10.1002/alz.12413.
    PubMed     Abstract available


  210. BOCHE D, Gordon MN
    Diversity of transcriptomic microglial phenotypes in aging and Alzheimer's disease.
    Alzheimers Dement. 2021 Jul 5. doi: 10.1002/alz.12389.
    PubMed     Abstract available


  211. BAO H, Liu Y, Zhang M, Chen Z, et al
    Increased beta-site APP cleaving enzyme 1-mediated insulin receptor cleavage in type 2 diabetes mellitus with cognitive impairment.
    Alzheimers Dement. 2021;17:1097-1108.
    PubMed     Abstract available


    June 2021
  212. ZHANG X, Farrell JJ, Tong T, Hu J, et al
    Association of mitochondrial variants and haplogroups identified by whole exome sequencing with Alzheimer's disease.
    Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12396.
    PubMed     Abstract available


  213. TEERLINK CC, Miller JB, Vance EL, Staley LA, et al
    Analysis of high-risk pedigrees identifies 12 candidate variants for Alzheimer's disease.
    Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12397.
    PubMed     Abstract available


  214. ZHONG W, Wu A, Berglund K, Gu X, et al
    Pathogenesis of sporadic Alzheimer's disease by deficiency of NMDA receptor subunit GluN3A.
    Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12398.
    PubMed     Abstract available


  215. JANELIDZE S, Palmqvist S, Leuzy A, Stomrud E, et al
    Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Abeta42/Abeta40 and p-tau.
    Alzheimers Dement. 2021 Jun 20. doi: 10.1002/alz.12395.
    PubMed     Abstract available


  216. BIRKENBIHL C, Salimi Y, Frohlich H
    Unraveling the heterogeneity in Alzheimer's disease progression across multiple cohorts and the implications for data-driven disease modeling.
    Alzheimers Dement. 2021 Jun 9. doi: 10.1002/alz.12387.
    PubMed     Abstract available


  217. LOPEZ-RODRIGUEZ AB, Hennessy E, Murray CL, Nazmi A, et al
    Acute systemic inflammation exacerbates neuroinflammation in Alzheimer's disease: IL-1beta drives amplified responses in primed astrocytes and neuronal network dysfunction.
    Alzheimers Dement. 2021 Jun 3. doi: 10.1002/alz.12341.
    PubMed     Abstract available


  218. TEMP AGM, Lutz MW, Trepel D, Tang Y, et al
    How Bayesian statistics may help answer some of the controversial questions in clinical research on Alzheimer's disease.
    Alzheimers Dement. 2021;17:917-919.
    PubMed    


  219. FRANZMEIER N, Ossenkoppele R, Brendel M, Rubinski A, et al
    The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Abeta-associated tau accumulation and cognitive decline.
    Alzheimers Dement. 2021 Jun 1. doi: 10.1002/alz.12371.
    PubMed     Abstract available


  220. RICHARD E, den Brok MGHE, van Gool WA
    Bayes analysis supports null hypothesis of anti-amyloid beta therapy in Alzheimer's disease.
    Alzheimers Dement. 2021;17:1051-1055.
    PubMed     Abstract available


  221. DE ERAUSQUIN GA, Snyder H, Carrillo M, Hosseini AA, et al
    The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning.
    Alzheimers Dement. 2021;17:1056-1065.
    PubMed     Abstract available


    May 2021
  222. SEXTON CE, Anstey KJ, Baldacci F, Barnum CJ, et al
    Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney.
    Alzheimers Dement. 2021 May 31. doi: 10.1002/alz.12380.
    PubMed     Abstract available


  223. O'BRYANT SE, Zhang F, Petersen M, Hall JR, et al
    A blood screening tool for detecting mild cognitive impairment and Alzheimer's disease among community-dwelling Mexican Americans and non-Hispanic Whites: A method for increasing representation of diverse populations in clinical research.
    Alzheimers Dement. 2021 May 31. doi: 10.1002/alz.12382.
    PubMed     Abstract available


  224. PANNUZZO M
    Beta-amyloid pore linked to controlled calcium influx into the cell: A new paradigm for Alzheimer's Disease.
    Alzheimers Dement. 2021 May 29. doi: 10.1002/alz.12373.
    PubMed     Abstract available


  225. SCHWAHN C, Frenzel S, Holtfreter B, Van der Auwera S, et al
    Effect of periodontal treatment on preclinical Alzheimer's disease-Results of a trial emulation approach.
    Alzheimers Dement. 2021 May 29. doi: 10.1002/alz.12378.
    PubMed     Abstract available


  226. RAJAN KB, Weuve J, Barnes LL, McAninch EA, et al
    Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060).
    Alzheimers Dement. 2021 May 27. doi: 10.1002/alz.12362.
    PubMed     Abstract available


  227. HAMPEL H, Shaw LM, Aisen P, Chen C, et al
    State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease.
    Alzheimers Dement. 2021 May 27. doi: 10.1002/alz.12372.
    PubMed     Abstract available


  228. JIANG Y, Zhou X, Ip FC, Chan P, et al
    Large-scale plasma proteomic profiling identifies a high-performance biomarker panel for Alzheimer's disease screening and staging.
    Alzheimers Dement. 2021 May 25. doi: 10.1002/alz.12369.
    PubMed     Abstract available


  229. APOSTOLOVA LG, Aisen P, Eloyan A, Fagan A, et al
    The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology.
    Alzheimers Dement. 2021 May 21. doi: 10.1002/alz.12350.
    PubMed     Abstract available


  230. STERN Y, Stallard E, Kinosian B, Zhu C, et al
    Validation and demonstration of a new comprehensive model of Alzheimer's disease progression.
    Alzheimers Dement. 2021 May 14. doi: 10.1002/alz.12336.
    PubMed     Abstract available


  231. HONG S, Dobricic V, Ohlei O, Bos I, et al
    TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels.
    Alzheimers Dement. 2021 May 14. doi: 10.1002/alz.12330.
    PubMed     Abstract available


  232. LIBIGER O, Shaw LM, Watson MH, Nairn AC, et al
    Longitudinal CSF proteomics identifies NPTX2 as a prognostic biomarker of Alzheimer's disease.
    Alzheimers Dement. 2021 May 13. doi: 10.1002/alz.12353.
    PubMed     Abstract available


  233. GUSTAVSSON A, Raket LL, Lilja M, Rutten-Jacobs L, et al
    Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study.
    Alzheimers Dement. 2021 May 13. doi: 10.1002/alz.12355.
    PubMed     Abstract available


  234. MORGAN DG, Mielke MM
    Knowledge gaps in Alzheimer's disease immune biomarker research.
    Alzheimers Dement. 2021 May 13. doi: 10.1002/alz.12342.
    PubMed     Abstract available


  235. OSSENKOPPELE R, Hansson O
    Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease.
    Alzheimers Dement. 2021 May 13. doi: 10.1002/alz.12356.
    PubMed     Abstract available


  236. MADRASI K, Das R, Mohmmadabdul H, Lin L, et al
    Systematic in silico analysis of clinically tested drugs for reducing amyloid-beta plaque accumulation in Alzheimer's disease.
    Alzheimers Dement. 2021 May 2. doi: 10.1002/alz.12312.
    PubMed     Abstract available



  237. Association commits $14 million to novel drug trials in rare form of Alzheimer's.
    Alzheimers Dement. 2021;17:910.
    PubMed    


  238. STANLEY J, Howlett SE, Dunn T, Rockwood K, et al
    The Clinician's Interview-Based Impression of Change (Plus caregiver input) and goal attainment in two dementia drug trials: Clinical meaningfulness and the initial treatment response.
    Alzheimers Dement. 2021;17:856-865.
    PubMed     Abstract available


  239. MIELKE MM, Przybelski SA, Lesnick TG, Kern S, et al
    Comparison of CSF neurofilament light chain, neurogranin, and tau to MRI markers.
    Alzheimers Dement. 2021;17:801-812.
    PubMed     Abstract available


  240. WOODWORTH DC, Nguyen HL, Khan Z, Kawas CH, et al
    Utility of MRI in the identification of hippocampal sclerosis of aging.
    Alzheimers Dement. 2021;17:847-855.
    PubMed     Abstract available


  241. COUSINS KAQ, Phillips JS, Irwin DJ, Lee EB, et al
    ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration.
    Alzheimers Dement. 2021;17:822-830.
    PubMed     Abstract available


    April 2021
  242. RANASINGHE KG, Petersen C, Kudo K, Mizuiri D, et al
    Reduced synchrony in alpha oscillations during life predicts post mortem neurofibrillary tangle density in early-onset and atypical Alzheimer's disease.
    Alzheimers Dement. 2021 Apr 21. doi: 10.1002/alz.12349.
    PubMed     Abstract available


  243. LI X, Tsolis KC, Koper MJ, Ronisz A, et al
    Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease.
    Alzheimers Dement. 2021 Apr 19. doi: 10.1002/alz.12345.
    PubMed     Abstract available


  244. BABILONI C, Arakaki X, Azami H, Bennys K, et al
    Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel.
    Alzheimers Dement. 2021 Apr 15. doi: 10.1002/alz.12311.
    PubMed     Abstract available


  245. MOELLER S, Sridhar J, Martersteck A, Coventry C, et al
    Functional decline in the aphasic variant of Alzheimer's disease.
    Alzheimers Dement. 2021 Apr 8. doi: 10.1002/alz.12331.
    PubMed     Abstract available


  246. MOLONEY CM, Lowe VJ, Murray ME
    Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research.
    Alzheimers Dement. 2021 Apr 2. doi: 10.1002/alz.12321.
    PubMed     Abstract available


  247. PROKOPENKO D, Morgan SL, Mullin K, Hofmann O, et al
    Whole-genome sequencing reveals new Alzheimer's disease-associated rare variants in loci related to synaptic function and neuronal development.
    Alzheimers Dement. 2021 Apr 2. doi: 10.1002/alz.12319.
    PubMed     Abstract available


  248. SABBAGH MN, Cummings J
    Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019".
    Alzheimers Dement. 2021;17:702-703.
    PubMed    


  249. KULLER LH, Lopez OL
    ENGAGE and EMERGE: Truth and consequences?
    Alzheimers Dement. 2021;17:692-695.
    PubMed     Abstract available


  250. BRAY MJC, Richey LN, Bryant BR, Krieg A, et al
    Traumatic brain injury alters neuropsychiatric symptomatology in all-cause dementia.
    Alzheimers Dement. 2021;17:686-691.
    PubMed     Abstract available


  251. PLANCHE V, Bouteloup V, Mangin JF, Dubois B, et al
    Clinical relevance of brain atrophy subtypes categorization in memory clinics.
    Alzheimers Dement. 2021;17:641-652.
    PubMed     Abstract available


  252. STAFFARONI AM, Asken BM, Casaletto KB, Fonseca C, et al
    Development and validation of the Uniform Data Set (v3.0) executive function composite score (UDS3-EF).
    Alzheimers Dement. 2021;17:574-583.
    PubMed     Abstract available


  253. KNOPMAN DS, Jones DT, Greicius MD
    Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019.
    Alzheimers Dement. 2021;17:696-701.
    PubMed     Abstract available


    March 2021
  254. CHONG JR, Ashton NJ, Karikari TK, Tanaka T, et al
    Plasma P-tau181 to Abeta42 ratio is associated with brain amyloid burden and hippocampal atrophy in an Asian cohort of Alzheimer's disease patients with concomitant cerebrovascular disease.
    Alzheimers Dement. 2021 Mar 31. doi: 10.1002/alz.12332.
    PubMed     Abstract available


  255. SHI L, Winchester LM, Westwood S, Baird AL, et al
    Replication study of plasma proteins relating to Alzheimer's pathology.
    Alzheimers Dement. 2021 Mar 31. doi: 10.1002/alz.12322.
    PubMed     Abstract available


  256. HANSSON O, Batrla R, Brix B, Carrillo MC, et al
    The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid beta and tau.
    Alzheimers Dement. 2021 Mar 31. doi: 10.1002/alz.12316.
    PubMed     Abstract available



  257. Register for May AAIC(R) Satellite Symposium and second Latinos & Alzheimer's symposium.
    Alzheimers Dement. 2021 Mar 31. doi: 10.1002/alz.12337.
    PubMed    


  258. AKHTER-KHAN SC, Tao Q, Ang TFA, Itchapurapu IS, et al
    Associations of loneliness with risk of Alzheimer's disease dementia in the Framingham Heart Study.
    Alzheimers Dement. 2021 Mar 24. doi: 10.1002/alz.12327.
    PubMed     Abstract available



  259. 2021 Alzheimer's disease facts and figures.
    Alzheimers Dement. 2021 Mar 23. doi: 10.1002/alz.12328.
    PubMed     Abstract available


  260. BECKMAN D, Chakrabarty P, Ott S, Dao A, et al
    A novel tau-based rhesus monkey model of Alzheimer's pathogenesis.
    Alzheimers Dement. 2021 Mar 18. doi: 10.1002/alz.12318.
    PubMed     Abstract available


  261. KOCIOLEK AJ, Fernandez KK, Jin Z, Cosentino S, et al
    Extrapyramidal signs and Alzheimer's disease prognosis in a multiethnic, community-based sample of demented elders.
    Alzheimers Dement. 2021 Mar 12. doi: 10.1002/alz.12309.
    PubMed     Abstract available


  262. DISBROW E, Stokes KY, Ledbetter C, Patterson J, et al
    Plasma hydrogen sulfide: A biomarker of Alzheimer's disease and related dementias.
    Alzheimers Dement. 2021 Mar 12. doi: 10.1002/alz.12305.
    PubMed     Abstract available


  263. FALGAS N, Walsh CM, Neylan TC, Grinberg LT, et al
    Deepen into sleep and wake patterns across Alzheimer's disease phenotypes.
    Alzheimers Dement. 2021 Mar 12. doi: 10.1002/alz.12304.
    PubMed     Abstract available


  264. RAHMAN M, White EM, Mills C, Thomas KS, et al
    Rural-urban differences in diagnostic incidence and prevalence of Alzheimer's disease and related dementias.
    Alzheimers Dement. 2021 Mar 4. doi: 10.1002/alz.12285.
    PubMed     Abstract available


  265. SALVADO G, Mila-Aloma M, Shekari M, Minguillon C, et al
    Cerebral amyloid-beta load is associated with neurodegeneration and gliosis: Mediation by p-tau and interactions with risk factors early in the Alzheimer's continuum.
    Alzheimers Dement. 2021 Mar 4. doi: 10.1002/alz.12245.
    PubMed     Abstract available


  266. TURNER DA, Degan S, Hoffmann U, Galeffi F, et al
    CVN-AD Alzheimer's mice show premature reduction in neurovascular coupling in response to spreading depression and anoxia compared to aged controls.
    Alzheimers Dement. 2021 Mar 3. doi: 10.1002/alz.12289.
    PubMed     Abstract available


  267. MASEREJIAN N, Krzywy H, Eaton S, Galvin JE, et al
    Cognitive measures lacking in EHR prior to dementia or Alzheimer's disease diagnosis.
    Alzheimers Dement. 2021 Mar 3. doi: 10.1002/alz.12280.
    PubMed     Abstract available


  268. SAITO ER, Miller JB, Harari O, Cruchaga C, et al
    Alzheimer's disease alters oligodendrocytic glycolytic and ketolytic gene expression.
    Alzheimers Dement. 2021 Mar 2. doi: 10.1002/alz.12310.
    PubMed     Abstract available


  269. LI Y, Xiong C, Aschenbrenner AJ, Chang CH, et al
    Item response theory analysis of the Clinical Dementia Rating.
    Alzheimers Dement. 2021;17:534-542.
    PubMed     Abstract available


  270. FANI L, Ahmad S, Ikram MK, Ghanbari M, et al
    Immunity and amyloid beta, total tau and neurofilament light chain: Findings from a community-based cohort study.
    Alzheimers Dement. 2021;17:446-456.
    PubMed     Abstract available


  271. GRANOT-HERSHKOVITZ E, Tarraf W, Kurniansyah N, Daviglus M, et al
    APOE alleles' association with cognitive function differs across Hispanic/Latino groups and genetic ancestry in the study of Latinos-investigation of neurocognitive aging (HCHS/SOL).
    Alzheimers Dement. 2021;17:466-474.
    PubMed     Abstract available


    February 2021
  272. ASHFORD MT, Veitch DP, Neuhaus J, Nosheny RL, et al
    The search for a convenient procedure to detect one of the earliest signs of Alzheimer's disease: A systematic review of the prediction of brain amyloid status.
    Alzheimers Dement. 2021 Feb 13. doi: 10.1002/alz.12253.
    PubMed     Abstract available


  273. BRICKMAN AM, Manly JJ, Honig LS, Sanchez D, et al
    Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study.
    Alzheimers Dement. 2021 Feb 13. doi: 10.1002/alz.12301.
    PubMed     Abstract available


  274. IZZO NJ, Yuede CM, LaBarbera KM, Limegrover CS, et al
    Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification.
    Alzheimers Dement. 2021 Feb 8. doi: 10.1002/alz.12302.
    PubMed     Abstract available


  275. BLEILE L
    Alzheimer's Association Update.
    Alzheimers Dement. 2021 Feb 4. doi: 10.1002/alz.12306.
    PubMed    


  276. WANG R, Qiu C, Dintica CS, Shang Y, et al
    Shared risk and protective factors between Alzheimer's disease and ischemic stroke: A population-based longitudinal study.
    Alzheimers Dement. 2021 Feb 1. doi: 10.1002/alz.12203.
    PubMed     Abstract available


  277. GUZMAN-VELEZ E, Zetterberg H, Fox-Fuller JT, Vila-Castelar C, et al
    Associations between plasma neurofilament light, in vivo brain pathology, and cognition in non-demented individuals with autosomal-dominant Alzheimer's disease.
    Alzheimers Dement. 2021 Feb 1. doi: 10.1002/alz.12248.
    PubMed     Abstract available


  278. GRISWOLD AJ, Celis K, Bussies PL, Rajabli F, et al
    Increased APOE epsilon4 expression is associated with the difference in Alzheimer's disease risk from diverse ancestral backgrounds.
    Alzheimers Dement. 2021 Feb 1. doi: 10.1002/alz.12287.
    PubMed     Abstract available


  279. HAGHANI A, Thorwald M, Morgan TE, Finch CE, et al
    The APOE gene cluster responds to air pollution factors in mice with coordinated expression of genes that differs by age in humans.
    Alzheimers Dement. 2021;17:175-190.
    PubMed     Abstract available


  280. CHEN XQ, Salehi A, Pearn ML, Overk C, et al
    Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
    Alzheimers Dement. 2021;17:271-292.
    PubMed     Abstract available


  281. BLUE EE, Thornton TA, Kooperberg C, Liu S, et al
    Non-coding variants in MYH11, FZD3, and SORCS3 are associated with dementia in women.
    Alzheimers Dement. 2021;17:215-225.
    PubMed     Abstract available


  282. DE LEEUW FA, Karamujic-Comic H, Tijms BM, Peeters CFW, et al
    Circulating metabolites are associated with brain atrophy and white matter hyperintensities.
    Alzheimers Dement. 2021;17:205-214.
    PubMed     Abstract available


    January 2021
  283. AYTON S, Portbury S, Kalinowski P, Agarwal P, et al
    Regional brain iron associated with deterioration in Alzheimer's disease: A large cohort study and theoretical significance.
    Alzheimers Dement. 2021 Jan 25. doi: 10.1002/alz.12282.
    PubMed     Abstract available


  284. SIMREN J, Leuzy A, Karikari TK, Hye A, et al
    The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.
    Alzheimers Dement. 2021 Jan 25. doi: 10.1002/alz.12283.
    PubMed     Abstract available


  285. GERMANN J, Elias GJB, Boutet A, Narang K, et al
    Brain structures and networks responsible for stimulation-induced memory flashbacks during forniceal deep brain stimulation for Alzheimer's disease.
    Alzheimers Dement. 2021 Jan 21. doi: 10.1002/alz.12238.
    PubMed     Abstract available


  286. BRYAN J, Mandan A, Kamat G, Gottschalk WK, et al
    Likelihood ratio statistics for gene set enrichment in Alzheimer's disease pathways.
    Alzheimers Dement. 2021 Jan 21. doi: 10.1002/alz.12223.
    PubMed     Abstract available


  287. LUCKETT PH, McCullough A, Gordon BA, Strain J, et al
    Modeling autosomal dominant Alzheimer's disease with machine learning.
    Alzheimers Dement. 2021 Jan 21. doi: 10.1002/alz.12259.
    PubMed     Abstract available


  288. LI HD, Funk CC, McFarland K, Dammer EB, et al
    Integrative functional genomic analysis of intron retention in human and mouse brain with Alzheimer's disease.
    Alzheimers Dement. 2021 Jan 21. doi: 10.1002/alz.12254.
    PubMed     Abstract available



  289. Alzheimer's Association International Conference Neuroscience Next focused on early career researchers across all of neuroscience.
    Alzheimers Dement. 2021;17:138-139.
    PubMed    


  290. CHIARI A, Vinceti G, Adani G, Tondelli M, et al
    Epidemiology of early onset dementia and its clinical presentations in the province of Modena, Italy.
    Alzheimers Dement. 2021;17:81-88.
    PubMed     Abstract available


    December 2020
  291. VAN HULLE C, Jonaitis EM, Betthauser TJ, Batrla R, et al
    An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum.
    Alzheimers Dement. 2020 Dec 18. doi: 10.1002/alz.12204.
    PubMed     Abstract available


  292. LYSSENKO NN, Pratico D
    ABCA7 and the altered lipidostasis hypothesis of Alzheimer's disease.
    Alzheimers Dement. 2020 Dec 17. doi: 10.1002/alz.12220.
    PubMed     Abstract available


  293. MOHAMMED H
    Recognizing African-American contributions to neurology: The role of Solomon Carter Fuller (1872-1953) in Alzheimer's disease research.
    Alzheimers Dement. 2020 Dec 15. doi: 10.1002/alz.12183.
    PubMed     Abstract available


  294. AUDRAIN M, Haure-Mirande JV, Mleczko J, Wang M, et al
    Reactive or transgenic increase in microglial TYROBP reveals a TREM2-independent TYROBP-APOE link in wild-type and Alzheimer's-related mice.
    Alzheimers Dement. 2020 Dec 12. doi: 10.1002/alz.12256.
    PubMed     Abstract available


  295. KIM YW, Al-Ramahi I, Koire A, Wilson SJ, et al
    Harnessing the paradoxical phenotypes of APOE varepsilon2 and APOE varepsilon4 to identify genetic modifiers in Alzheimer's disease.
    Alzheimers Dement. 2020 Dec 7. doi: 10.1002/alz.12240.
    PubMed     Abstract available


  296. FRYE BM, Craft S, Register TC, Andrews RN, et al
    Diet, psychosocial stress, and Alzheimer's disease-related neuroanatomy in female nonhuman primates.
    Alzheimers Dement. 2020 Dec 3. doi: 10.1002/alz.12232.
    PubMed     Abstract available


    November 2020
  297. KARIKARI TK, Emersic A, Vrillon A, Lantero-Rodriguez J, et al
    Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosis.
    Alzheimers Dement. 2020 Nov 30. doi: 10.1002/alz.12236.
    PubMed     Abstract available


  298. LLIBRE-GUERRA JJ, Li Y, Allegri RF, Mendez PC, et al
    Dominantly inherited Alzheimer's disease in Latin America: Genetic heterogeneity and clinical phenotypes.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12227.
    PubMed     Abstract available


  299. DUENAS MR, Snyder PJ
    Alzheimer's team care approach-akin to diabetes-in the development, validation, and population assessment of retinal biomarkers for disease.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12234.
    PubMed     Abstract available


  300. SPENCER BE, Digma LA, Jennings RG, Brewer JB, et al
    Gene- and age-informed screening for preclinical Alzheimer's disease trials.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12207.
    PubMed     Abstract available


  301. HITHERSAY R, Baksh RA, Startin CM, Wijeratne P, et al
    Optimal age and outcome measures for Alzheimer's disease prevention trials in people with Down syndrome.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12222.
    PubMed     Abstract available


  302. PENTZ R, Iulita MF, Ducatenzeiler A, Videla L, et al
    Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study.
    Alzheimers Dement. 2020 Nov 23. doi: 10.1002/alz.12229.
    PubMed     Abstract available


  303. MONTAL V, Vilaplana E, Pegueroles J, Bejanin A, et al
    Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease.
    Alzheimers Dement. 2020 Nov 16. doi: 10.1002/alz.12224.
    PubMed     Abstract available


  304. JESSEN F, Kleineidam L, Wolfsgruber S, Bickel H, et al
    Prediction of dementia of Alzheimer type by different types of subjective cognitive decline.
    Alzheimers Dement. 2020 Nov 2. doi: 10.1002/alz.12163.
    PubMed     Abstract available



  305. Alzheimer's Association pays tribute to former Chief Science Officer William (Bill) Thies, PhD.
    Alzheimers Dement. 2020;16:1600-1605.
    PubMed    


    October 2020
  306. SOHEILI-NEZHAD S, van der Linden RJ, Olde Rikkert M, Sprooten E, et al
    Long genes are more frequently affected by somatic mutations and show reduced expression in Alzheimer's disease: Implications for disease etiology.
    Alzheimers Dement. 2020 Oct 19. doi: 10.1002/alz.12211.
    PubMed     Abstract available


  307. ARNSTEN AFT, Datta D, Tredici KD, Braak H, et al
    Hypothesis: Tau pathology is an initiating factor in sporadic Alzheimer's disease.
    Alzheimers Dement. 2020 Oct 19. doi: 10.1002/alz.12192.
    PubMed     Abstract available


  308. WESSELS AM, Lines C, Stern RA, Kost J, et al
    Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease.
    Alzheimers Dement. 2020 Oct 13. doi: 10.1002/alz.12164.
    PubMed     Abstract available


  309. MECCA AP, van Dyck CH
    Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
    Alzheimers Dement. 2020 Oct 12. doi: 10.1002/alz.12190.
    PubMed    


  310. SNYDER PJ, Alber J, Alt C, Bain LJ, et al
    Retinal imaging in Alzheimer's and neurodegenerative diseases.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12179.
    PubMed     Abstract available


  311. THUNELL J, Chen Y, Joyce G, Barthold D, et al
    Drug therapies for chronic conditions and risk of Alzheimer's disease and related dementias: A scoping review.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12175.
    PubMed     Abstract available


  312. JAIN S, Rosenbaum PR, Reiter JG, Hoffman G, et al
    Using Medicare claims in identifying Alzheimer's disease and related dementias.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12199.
    PubMed     Abstract available


  313. HOU X, Watzlawik JO, Cook C, Liu CC, et al
    Mitophagy alterations in Alzheimer's disease are associated with granulovacuolar degeneration and early tau pathology.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12198.
    PubMed     Abstract available


  314. BUBU OM, Umasabor-Bubu OQ, Turner AD, Parekh A, et al
    Self-reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease time-dependent progression.
    Alzheimers Dement. 2020 Oct 8. doi: 10.1002/alz.12184.
    PubMed     Abstract available


    September 2020
  315. FRANCESCO DL, Koch G
    Synaptic impairment: The new battlefield of Alzheimer's disease.
    Alzheimers Dement. 2020 Sep 18. doi: 10.1002/alz.12189.
    PubMed    



  316. 36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease.
    Alzheimers Dement. 2020 Sep 13. doi: 10.1002/alz.12172.
    PubMed     Abstract available


  317. JIA L, Xu H, Chen S, Wang X, et al
    The APOE epsilon4 exerts differential effects on familial and other subtypes of Alzheimer's disease.
    Alzheimers Dement. 2020 Sep 3. doi: 10.1002/alz.12153.
    PubMed     Abstract available


  318. DE LEON J, Grasso SM, Welch A, Miller Z, et al
    Effects of bilingualism on age at onset in two clinical Alzheimer's disease variants.
    Alzheimers Dement. 2020 Sep 3. doi: 10.1002/alz.12170.
    PubMed     Abstract available


    August 2020
  319. LIU CC, Yamazaki Y, Heckman MG, Martens YA, et al
    Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease.
    Alzheimers Dement. 2020 Aug 22. doi: 10.1002/alz.12104.
    PubMed     Abstract available


  320. FRISONI GB, Molinuevo JL, Altomare D, Carrera E, et al
    Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies.
    Alzheimers Dement. 2020 Aug 20. doi: 10.1002/alz.12132.
    PubMed     Abstract available


  321. FINSTERWALDER S, Vlegels N, Gesierich B, Araque Caballero MA, et al
    Small vessel disease more than Alzheimer's disease determines diffusion MRI alterations in memory clinic patients.
    Alzheimers Dement. 2020 Aug 18. doi: 10.1002/alz.12150.
    PubMed     Abstract available


  322. LIN PJ, Cohen JT, Neumann PJ
    Preparing the health-care system to pay for new Alzheimer's drugs.
    Alzheimers Dement. 2020 Aug 18. doi: 10.1002/alz.12155.
    PubMed     Abstract available


  323. DENNY A, Streitz M, Stock K, Balls-Berry JE, et al
    Perspective on the "African American participation in Alzheimer disease research: Effective strategies" workshop, 2018.
    Alzheimers Dement. 2020 Aug 17. doi: 10.1002/alz.12160.
    PubMed     Abstract available


  324. WU CY, Ouk M, Wong YY, Anita NZ, et al
    Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status.
    Alzheimers Dement. 2020 Aug 16. doi: 10.1002/alz.12161.
    PubMed     Abstract available


  325. MOK VCT, Pendlebury S, Wong A, Alladi S, et al
    Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future.
    Alzheimers Dement. 2020 Aug 12. doi: 10.1002/alz.12143.
    PubMed     Abstract available


  326. JIA L, Zhu M, Kong C, Pang Y, et al
    Blood neuro-exosomal synaptic proteins predict Alzheimer's disease at the asymptomatic stage.
    Alzheimers Dement. 2020 Aug 10. doi: 10.1002/alz.12166.
    PubMed     Abstract available


  327. NHO K, Nudelman K, Allen M, Hodges A, et al
    Genome-wide transcriptome analysis identifies novel dysregulated genes implicated in Alzheimer's pathology.
    Alzheimers Dement. 2020 Aug 5. doi: 10.1002/alz.12092.
    PubMed     Abstract available


    July 2020
  328. GUSTAFSON DR, Backman K, Scarmeas N, Stern Y, et al
    Dietary fatty acids and risk of Alzheimer's disease and related dementias: Observations from the Washington Heights-Hamilton Heights-Inwood Columbia Aging Project (WHICAP).
    Alzheimers Dement. 2020 Jul 27. doi: 10.1002/alz.12154.
    PubMed     Abstract available


  329. BOADA M, Lopez OL, Olazaran J, Nunez L, et al
    A randomized, controlled clinical trial of plasma exchange with albumin replacement for Alzheimer's disease: Primary results of the AMBAR Study.
    Alzheimers Dement. 2020 Jul 27. doi: 10.1002/alz.12137.
    PubMed     Abstract available


  330. VIDONI ED, Choi IY, Lee P, Reed G, et al
    Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients.
    Alzheimers Dement. 2020 Jul 27. doi: 10.1002/alz.12156.
    PubMed     Abstract available


  331. KLING MA, Goodenowe DB, Senanayake V, MahmoudianDehkordi S, et al
    Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau.
    Alzheimers Dement. 2020 Jul 27. doi: 10.1002/alz.12110.
    PubMed     Abstract available


  332. XU W, Tan L, Su BJ, Yu H, et al
    Sleep characteristics and cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact older adults: The CABLE study.
    Alzheimers Dement. 2020 Jul 13. doi: 10.1002/alz.12117.
    PubMed     Abstract available


    June 2020
  333. CASELLI RJ, Knopman DS, Bu G
    An agnostic reevaluation of the amyloid cascade hypothesis of Alzheimer's disease pathogenesis: The role of APP homeostasis.
    Alzheimers Dement. 2020 Jun 26. doi: 10.1002/alz.12124.
    PubMed     Abstract available


  334. LUTZ MW, Luo S, Williamson DE, Chiba-Falek O, et al
    Shared genetic etiology underlying late-onset Alzheimer's disease and posttraumatic stress syndrome.
    Alzheimers Dement. 2020 Jun 26. doi: 10.1002/alz.12128.
    PubMed     Abstract available


  335. EREN E, Hunt JFV, Shardell M, Chawla S, et al
    Extracellular vesicle biomarkers of Alzheimer's disease associated with sub-clinical cognitive decline in late middle age.
    Alzheimers Dement. 2020 Jun 26. doi: 10.1002/alz.12130.
    PubMed     Abstract available



  336. New Thinking About Thinking, Part 3. Advice on preparing a successful manuscript for Alzheimer's & Dementia.
    Alzheimers Dement. 2020 Jun 24. doi: 10.1002/alz.12141.
    PubMed    


  337. MILA-ALOMA M, Salvado G, Gispert JD, Vilor-Tejedor N, et al
    Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer's continuum.
    Alzheimers Dement. 2020 Jun 23. doi: 10.1002/alz.12131.
    PubMed     Abstract available


  338. SHERVA R, Gross A, Mukherjee S, Koesterer R, et al
    Genome-wide association study of rate of cognitive decline in Alzheimer's disease patients identifies novel genes and pathways.
    Alzheimers Dement. 2020 Jun 23. doi: 10.1002/alz.12106.
    PubMed     Abstract available


  339. AZAR M, Chapman S, Gu Y, Leverenz JB, et al
    Cognitive tests aid in clinical differentiation of Alzheimer's disease versus Alzheimer's disease with Lewy body disease: Evidence from a pathological study.
    Alzheimers Dement. 2020 Jun 19. doi: 10.1002/alz.12120.
    PubMed     Abstract available


  340. SNYDER HM, Bain LJ, Brickman AM, Carrillo MC, et al
    Further understanding the connection between Alzheimer's disease and Down syndrome.
    Alzheimers Dement. 2020 Jun 16. doi: 10.1002/alz.12112.
    PubMed     Abstract available


  341. SWERDLOW RH, Hui D, Chalise P, Sharma P, et al
    Exploratory analysis of mtDNA haplogroups in two Alzheimer's longitudinal cohorts.
    Alzheimers Dement. 2020 Jun 16. doi: 10.1002/alz.12119.
    PubMed     Abstract available


  342. COCROFT S, Welsh-Bohmer KA, Plassman BL, Chanti-Ketterl M, et al
    Racially diverse participant registries to facilitate the recruitment of African Americans into presymptomatic Alzheimer's disease studies.
    Alzheimers Dement. 2020 Jun 16. doi: 10.1002/alz.12048.
    PubMed     Abstract available


  343. BERMEJO-PAREJA F, Del Ser T, Valenti M, de la Fuente M, et al
    Salivary lactoferrin as biomarker for Alzheimer's disease: Brain-immunity interactions.
    Alzheimers Dement. 2020 Jun 16. doi: 10.1002/alz.12107.
    PubMed     Abstract available


  344. BI D, Wen L, Wu Z, Shen Y, et al
    GABAergic dysfunction in excitatory and inhibitory (E/I) imbalance drives the pathogenesis of Alzheimer's disease.
    Alzheimers Dement. 2020 Jun 16. doi: 10.1002/alz.12088.
    PubMed     Abstract available


  345. GENTREAU M, Chuy V, Feart C, Samieri C, et al
    Refined carbohydrate-rich diet is associated with long-term risk of dementia and Alzheimer's disease in apolipoprotein E epsilon4 allele carriers.
    Alzheimers Dement. 2020 Jun 7. doi: 10.1002/alz.12114.
    PubMed     Abstract available


  346. FIRTH NC, Primativo S, Brotherhood E, Young AL, et al
    Sequences of cognitive decline in typical Alzheimer's disease and posterior cortical atrophy estimated using a novel event-based model of disease progression.
    Alzheimers Dement. 2020 Jun 2. doi: 10.1002/alz.12083.
    PubMed     Abstract available


    May 2020
  347. ORDING AG, Horvath-Puho E, Veres K, Glymour MM, et al
    Cancer and risk of Alzheimer's disease: Small association in a nationwide cohort study.
    Alzheimers Dement. 2020 May 20. doi: 10.1002/alz.12090.
    PubMed     Abstract available


  348. KNOPMAN D, Lemere CA, Lamb BT, Craft S, et al
    Scientific Advising and Reviewing: On strengthening the bond between the Alzheimer's Association and the scientific community.
    Alzheimers Dement. 2020 May 19. doi: 10.1002/alz.12059.
    PubMed     Abstract available


  349. RIOS-ROMENETS S, Lopera F, Sink KM, Hu N, et al
    Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal-Dominant Alzheimer's Disease Colombia Trial.
    Alzheimers Dement. 2020 May 17. doi: 10.1002/alz.12109.
    PubMed     Abstract available


  350. MECCA AP, Chen MK, O'Dell RS, Naganawa M, et al
    In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET.
    Alzheimers Dement. 2020 May 13. doi: 10.1002/alz.12097.
    PubMed     Abstract available


  351. MOORE EE, Gifford KA, Khan OA, Liu D, et al
    Cerebrospinal fluid biomarkers of neurodegeneration, synaptic dysfunction, and axonal injury relate to atrophy in structural brain regions specific to Alzheimer's disease.
    Alzheimers Dement. 2020 May 6. doi: 10.1002/alz.12087.
    PubMed     Abstract available


  352. RENTZ DM, Wessels AM, Bain LJ, Weber CJ, et al
    Clinical meaningfulness addressed at Alzheimer's Association Research Roundtable.
    Alzheimers Dement. 2020;16:814.
    PubMed    


    April 2020
  353. JORGENSEN IF, Aguayo-Orozco A, Lademann M, Brunak S, et al
    Age-stratified longitudinal study of Alzheimer's and vascular dementia patients.
    Alzheimers Dement. 2020 Apr 27. doi: 10.1002/alz.12091.
    PubMed     Abstract available


  354. DE FLORES R, Wisse LEM, Das SR, Xie L, et al
    Contribution of mixed pathology to medial temporal lobe atrophy in Alzheimer's disease.
    Alzheimers Dement. 2020 Apr 22. doi: 10.1002/alz.12079.
    PubMed     Abstract available


  355. MURAOKA S, DeLeo AM, Sethi MK, Yukawa-Takamatsu K, et al
    Proteomic and biological profiling of extracellular vesicles from Alzheimer's disease human brain tissues.
    Alzheimers Dement. 2020 Apr 17. doi: 10.1002/alz.12089.
    PubMed     Abstract available


  356. TRARES K, Gao X, Perna L, Rujescu D, et al
    Associations of urinary 8-iso-prostaglandin F2alpha levels with all-cause dementia, Alzheimer's disease, and vascular dementia incidence: results from a prospective cohort study.
    Alzheimers Dement. 2020 Apr 12. doi: 10.1002/alz.12081.
    PubMed     Abstract available


  357. LOPES ALVES I, Collij LE, Altomare D, Frisoni GB, et al
    Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study.
    Alzheimers Dement. 2020 Apr 12. doi: 10.1002/alz.12069.
    PubMed     Abstract available


  358. DONOHUE MC, Model F, Delmar P, Volye N, et al
    Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach.
    Alzheimers Dement. 2020 Apr 8. doi: 10.1002/alz.12058.
    PubMed     Abstract available


  359. GEERTS H, Spiros A
    Learning from amyloid trials in Alzheimer's disease. A virtual patient analysis using a quantitative systems pharmacology approach.
    Alzheimers Dement. 2020 Apr 7. doi: 10.1002/alz.12082.
    PubMed     Abstract available


  360. CABALLERO MAA, Song Z, Rubinski A, Duering M, et al
    Age-dependent amyloid deposition is associated with white matter alterations in cognitively normal adults during the adult life span.
    Alzheimers Dement. 2020;16:651-661.
    PubMed     Abstract available


    March 2020

  361. Alzheimer's Disease Research Enterprise in the Era of COVID-19/SARS-CoV-2.
    Alzheimers Dement. 2020 Mar 22. doi: 10.1002/alz.12093.
    PubMed    



  362. 2020 Alzheimer's disease facts and figures.
    Alzheimers Dement. 2020 Mar 10. doi: 10.1002/alz.12068.
    PubMed     Abstract available


  363. JANSSEN O, Vos SJB, Garcia-Negredo G, Tochel C, et al
    Real-world evidence in Alzheimer's disease: The ROADMAP Data Cube.
    Alzheimers Dement. 2020;16:461-471.
    PubMed     Abstract available


  364. LOWE VJ, Lundt ES, Albertson SM, Min HK, et al
    Tau-positron emission tomography correlates with neuropathology findings.
    Alzheimers Dement. 2020;16:561-571.
    PubMed     Abstract available


  365. PAPP KV, Buckley R, Mormino E, Maruff P, et al
    Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD.
    Alzheimers Dement. 2020;16:552-560.
    PubMed     Abstract available


    February 2020
  366. XIONG C, Luo J, Coble D, Agboola F, et al
    Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia.
    Alzheimers Dement. 2020 Feb 17. doi: 10.1002/alz.12060.
    PubMed     Abstract available


  367. SCHAFFERT J, LoBue C, White CL 3rd, Wilmoth K, et al
    Risk factors for earlier dementia onset in autopsy-confirmed Alzheimer's disease, mixed Alzheimer's with Lewy bodies, and pure Lewy body disease.
    Alzheimers Dement. 2020 Feb 11. doi: 10.1002/alz.12049.
    PubMed     Abstract available


  368. FRANZMEIER N, Koutsouleris N, Benzinger T, Goate A, et al
    Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease-informed machine-learning.
    Alzheimers Dement. 2020 Feb 11. doi: 10.1002/alz.12032.
    PubMed     Abstract available



  369. Bill Gates funds $10 million grant to Alzheimer's Association to fuel research for Alzheimer's treatment.
    Alzheimers Dement. 2020;16:384.
    PubMed    


  370. ANTONELL A, Tort-Merino A, Rios J, Balasa M, et al
    Synaptic, axonal damage and inflammatory cerebrospinal fluid biomarkers in neurodegenerative dementias.
    Alzheimers Dement. 2020;16:262-272.
    PubMed     Abstract available


  371. ANGULO SL, Henzi T, Neymotin SA, Suarez MD, et al
    Amyloid pathology-produced unexpected modifications of calcium homeostasis in hippocampal subicular dendrites.
    Alzheimers Dement. 2020;16:251-261.
    PubMed     Abstract available


    January 2020
  372. HERRING WJ, Ceesay P, Snyder E, Bliwise D, et al
    Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial.
    Alzheimers Dement. 2020 Jan 15. doi: 10.1002/alz.12035.
    PubMed     Abstract available


  373. JIA L, Fu Y, Shen L, Zhang H, et al
    PSEN1, PSEN2, and APP mutations in 404 Chinese pedigrees with familial Alzheimer's disease.
    Alzheimers Dement. 2020;16:178-191.
    PubMed     Abstract available


  374. SNYDER PJ, Snyder HM, Bain LJ
    Retinal imaging think tank convened by the Alzheimer's Association to examine its promise in the early detection of Alzheimer's.
    Alzheimers Dement. 2020;16:244.
    PubMed    


  375. ALBER J, Goldfarb D, Thompson LI, Arthur E, et al
    Developing retinal biomarkers for the earliest stages of Alzheimer's disease: What we know, what we don't, and how to move forward.
    Alzheimers Dement. 2020;16:229-243.
    PubMed     Abstract available


  376. PATHAK GA, Zhou Z, Silzer TK, Barber RC, et al
    Two-stage Bayesian GWAS of 9576 individuals identifies SNP regions that are targeted by miRNAs inversely expressed in Alzheimer's and cancer.
    Alzheimers Dement. 2020;16:162-177.
    PubMed     Abstract available


  377. ASCHENBRENNER AJ, James BD, McDade E, Wang G, et al
    Awareness of genetic risk in the Dominantly Inherited Alzheimer Network (DIAN).
    Alzheimers Dement. 2020;16:219-228.
    PubMed     Abstract available


  378. LINARD M, Letenneur L, Garrigue I, Doize A, et al
    Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer's disease.
    Alzheimers Dement. 2020;16:200-208.
    PubMed     Abstract available


  379. KAPLOW J, Vandijck M, Gray J, Kanekiyo M, et al
    Concordance of Lumipulse cerebrospinal fluid t-tau/Abeta42 ratio with amyloid PET status.
    Alzheimers Dement. 2020;16:144-152.
    PubMed     Abstract available


    December 2019
  380. ELAHI FM, Casaletto KB, La Joie R, Walters SM, et al
    Plasma biomarkers of astrocytic and neuronal dysfunction in early- and late-onset Alzheimer's disease.
    Alzheimers Dement. 2019 Dec 23. pii: S1552-5260(19)35373.
    PubMed     Abstract available


  381. SABBAGH M, Sadowsky C, Tousi B, Agronin ME, et al
    Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease.
    Alzheimers Dement. 2019 Dec 23. pii: S1552-5260(19)35367.
    PubMed     Abstract available


    November 2019
  382. JANSSEN O, Vos SJB, Garcia-Negredo G, Tochel C, et al
    Real-world evidence in Alzheimer's disease: The ROADMAP Data Cube.
    Alzheimers Dement. 2019 Nov 27. pii: S1552-5260(19)35487.
    PubMed     Abstract available


  383. ANDREWS SJ, Goate A, Anstey KJ
    Association between alcohol consumption and Alzheimer's disease: A Mendelian randomization study.
    Alzheimers Dement. 2019 Nov 27. pii: S1552-5260(19)35486.
    PubMed     Abstract available


  384. GONZALEZ HM, Tarraf W, Fornage M, Gonzalez KA, et al
    A research framework for cognitive aging and Alzheimer's disease among diverse US Latinos: Design and implementation of the Hispanic Community Health Study/Study of Latinos-Investigation of Neurocognitive Aging (SOL-INCA).
    Alzheimers Dement. 2019 Nov 20. pii: S1552-5260(19)35362.
    PubMed     Abstract available


  385. TOLAR M, Abushakra S, Sabbagh M
    The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis.
    Alzheimers Dement. 2019 Nov 4. pii: S1552-5260(19)35450.
    PubMed     Abstract available



  386. Corrigendum to "AMYPAD Diagnostic and Patient Management Study: Rationale and design" [Alzheimer's & Dementia 2019;15:388-99].
    Alzheimers Dement. 2019;15:1505.
    PubMed    


    October 2019
  387. ISAACSON RS, Hristov H, Saif N, Hackett K, et al
    Individualized clinical management of patients at risk for Alzheimer's dementia.
    Alzheimers Dement. 2019 Oct 31. pii: S1552-5260(19)35368.
    PubMed     Abstract available


  388. PULINA MV, Hopkins M, Haroutunian V, Greengard P, et al
    C99 selectively accumulates in vulnerable neurons in Alzheimer's disease.
    Alzheimers Dement. 2019 Oct 30. pii: S1552-5260(19)35370.
    PubMed     Abstract available


  389. OSSENKOPPELE R, Lyoo CH, Sudre CH, van Westen D, et al
    Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease.
    Alzheimers Dement. 2019 Oct 28. pii: S1552-5260(19)35375.
    PubMed     Abstract available


  390. BROSSERON F, Kolbe CC, Santarelli F, Carvalho S, et al
    Multicenter Alzheimer's and Parkinson's disease immune biomarker verification study.
    Alzheimers Dement. 2019 Oct 17. pii: S1552-5260(19)35352.
    PubMed     Abstract available


  391. STOCKER H, Nabers A, Perna L, Mollers T, et al
    Prediction of Alzheimer's disease diagnosis within 14 years through Abeta misfolding in blood plasma compared to APOE4 status, and other risk factors.
    Alzheimers Dement. 2019 Oct 11. pii: S1552-5260(19)35349.
    PubMed     Abstract available


  392. GLEASON CE, Norton D, Zuelsdorff M, Benton SF, et al
    Association between enrollment factors and incident cognitive impairment in Blacks and Whites: Data from the Alzheimer's Disease Center.
    Alzheimers Dement. 2019 Oct 6. pii: S1552-5260(19)35138.
    PubMed     Abstract available


  393. OGINO E, Manly JJ, Schupf N, Mayeux R, et al
    Current and past leisure time physical activity in relation to risk of Alzheimer's disease in older adults.
    Alzheimers Dement. 2019 Oct 3. pii: S1552-5260(19)35136.
    PubMed     Abstract available


  394. EHRHARDT S, Porsteinsson AP, Munro CA, Rosenberg PB, et al
    Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.
    Alzheimers Dement. 2019 Oct 3. pii: S1552-5260(19)35112.
    PubMed     Abstract available


    September 2019
  395. MCRAE-MCKEE K, Udeh-Momoh CT, Price G, Bajaj S, et al
    Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a "gray zone"?
    Alzheimers Dement. 2019 Sep 26. pii: S1552-5260(19)35133.
    PubMed     Abstract available


  396. BLUE EE, Horimoto ARVR, Mukherjee S, Wijsman EM, et al
    Local ancestry at APOE modifies Alzheimer's disease risk in Caribbean Hispanics.
    Alzheimers Dement. 2019 Sep 25. pii: S1552-5260(19)35348.
    PubMed     Abstract available


  397. SCHAEFER KR, Noonan C, Mosley M, Smith J, et al
    Differences in service utilization at an urban tribal health organization before and after Alzheimer's disease or related dementia diagnosis: A cohort study.
    Alzheimers Dement. 2019 Sep 20. pii: S1552-5260(19)35111.
    PubMed     Abstract available


    August 2019
  398. MC ARDLE R, Galna B, Donaghy P, Thomas A, et al
    Do Alzheimer's and Lewy body disease have discrete pathological signatures of gait?
    Alzheimers Dement. 2019 Aug 30. pii: S1552-5260(19)35120.
    PubMed     Abstract available


  399. ELDADAH BA, Fazio EM, McLinden KA
    Lucidity in dementia: A perspective from the NIA.
    Alzheimers Dement. 2019;15:1104-1106.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Alzheimer's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: